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Abstract 
Systems formed by the supramolecular assemblages of organic molecules known as 
organogelators and hydrogelators are currently, and only recently, a subject of great attention 
and promise.  In this context, low molecular weight gelators (LMWGs) are of particular interest 
because they provide a bottom-up approach to the formation of supramolecular architectures 
through self-assembly. Gelator molecules do so via the initial formation of a one-dimensional 
array of individual molecules bound non-covalently through forces such as: hydrogen bonds, 
electrostatic forces, Van der Waals interactions, and other weak forces such as π-π interactions.  
These interactions then lead to secondary structure formation through a similar assembly 
mechanism.  Understanding the gelation process through characterization techniques is critical 
to the development of a design rationale for gelator molecules. Past and current research 
performed by the Wang group indicates that analogues of various 4,6-benzylidene acetals form 
stable gels in organic, aqueous, and organic/aqueous solvents at varying concentrations.  The 
basis of varying the 4,6-protecting groups on glucose and glucosamine derivatives is to discern 
the relative structure activity relationships of these systems, and as well to fabricate functional 
systems which respond to external stimulus.  Stimuli responsive or trigger release gel systems 
formed by sugar based low molecular weight gelators (LMWGs) have applications as smart 
biocompatible materials, and such responsiveness in various media was explored and 
developed to determine the feasibility of such applications using monosaccharide derivatives. 
 
Keywords:  Low Molecular Weight Gelators, Organogelator, Hydrogelator, Self-Assembly, Soft 
Material, Carbohydrates, Sugars 
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Chapter I. Introduction 
 
 
1.  Gelators 
 
 
Gelators are organic molecules which form soft materials known as “gels,” when incorporated 
into a solvent system.  The molecular architecture of gels is constituted primarily of the gelling 
agent and a fluid which can be of an organic or aqueous nature. This 3-dimensional viscoelastic 
material is essentially a scaffold or matrix of gel molecules networked and entangled in such a 
way that solvent molecules become trapped in pockets or chambers within the matrix 
formation. The two main types of gels are known as polymer gels which may as well be referred 
to as chemical gels, or low molecular weight gelators which may as well be referred to as 
physical gels.  One of these two primary types of gels known as polymer or chemical gels will 
not be extensively described in this thesis, although they are of great importance in the field of 
gel materials.  Polymer gels are made up, as the moniker suggests, of a polymer network which 
forms a scaffold or gel ‘mesh,’ which entraps solvent molecules within pockets formed by the 
polymeric material (Figure 1.1).  To date, there are already extensive uses of polymer gels in a 
 
Figure 1.1  Depiction of a gel mesh created by a polymeric material 
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variety of applications. Bhosale et al used polymer hydrogels for particle dispersion1, and as 
scaffolds to grow size-controlled particles. The electroacoustics of these systems were then 
analyzed to profile particle dynamic electrophoretic mobility within the gel mesh, which was 
found to be directly related to the cross-link density of the polymer matrix.  Tejraj Aminabhavi 
et al  employed a blend of microspheres of gelatin and hydroxyethyl cellulose to investigate the 
controlled release of theophylline (THP), an antiasthmatic drug, using a water-in-oil emulsion 
technique2.  Other important applications of polymer gels include but are not limited to: gel 
electrophoresis, as thickening agents, for topical drug delivery therapy, scaffolds for controlled 
drug release, tissue engineering, wound dressings, anti-adhesion materials, candles, diapers, 
fire retardants, hot & cold therapy packs, waste stabilization and environmental remediation, 
etc. Polymeric gels are indeed important in the applications to which they pertain, but are 
largely restricted to uses typically unique to non-thermoreversable superstructures.   
Supramolecular or physical gels, in particular the assemblages of small molecules which form 
gels via non-covalent intermolecular interactions, are soft novel materials which have several 
current and potential utilities.  Such molecules are known as “Low Molecular Weight Gelators,” 
or LMWGs.  Materials such as LMWGs are capable of being thermoreversably formed due to 
the types of intermolecular bonds associated with the matrix formation, and their applications 
extend to some of the aforementioned polymer gel applications in addition to having some 
exclusive uses4,5.  Such non-covalent interactions include: hydrogen bonding, π-π stacking, and 
Van Der Waals interactions. An example of a tetrathiofulvalene (TTF) species’ stacking array 
which is principally held together by such forces is illustrated below in Figure 1.2.  
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Figure 1.2  An intermolecular bonding array of TTF gelators depicting the various non-covalent 
interactions associated with LMWGs. Reprinted with permission from: Wang, X.; Xing, L.; Cao, W.; Li, X.; 
Chen, B.; Tung, C.; Wu, L.; Langmuir. Copyright 2011 American Chemical Society 
 
The well established and yet still rapidly expanding field of LMWGs currently delivers a variety 
of useful materials, which will perhaps one day be considered indispensable as critical materials 
for everyday utilities from industrial, pharmaceutical, and common consumer applications.  The 
characteristic property of thermoreversability exhibited by LMWGs, entitles them to some 
niche applications, which include but are not limited to the advanced materials applications 
such as:  pharmaceuticals, food, drug-delivery, biomimetics, enzyme-immobilization matrices, 
liquid crystalline materials, as templates for preparing other novel compounds, mechanical 
actuators, and in catalysis6.  For example, trimethoxysilane bis urea 1 (Figure 1.3), which was 
synthesized in a one-pot reaction, was tested in a variety of organic/aqueous solvents, where 
the content of each of the gels formed is only 1% gelator molecule by weight3: 
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Figure 1.3 Trimethoxysilane bis urea 1 
 
 
Figure 1.4   An illustration of the thermoreversability of TTF LMWGs.  The gel to sol transition can take 
place several times over before this functional property is exhausted. Reprinted with permission from: 
Wang, X.; Xing, L.; Cao, W.; Li, X.; Chen, B.; Tung, C.; Wu, L.; Langmuir. Copyright 2011 American 
Chemical Society 
 
The determination of what exactly constitutes a gel is essentially a crude measurement of the 
human eye.  The aforementioned “crude measurement” can be performed simply by observing 
a gelatinous material as being suspended for a short duration, such as in the upside down vial 
to the right in Figure 4.1.  A gel is characterized by its flow property, which is solid-like under 
rheological considerations, yet has a composition which is predominantly liquid, with 
proportions which are commonly 99% liquid and about 1% gelator molecule.  A more technical 
proposition was introduced by Flory, who defined a gel as: 1)”… a continuous structure with 
macroscopic dimensions that is permanent on the time scale of an analytical experiment and 2) 
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is solidlike in its rheological behavior.”4  This measurement can as well be made by subjecting a 
gelatinous material to the “dropping ball method,” which determines the gel integrity under 
temperature variances.  This experiment is carried out by introducing a metal ball to the gel at a 
particular temperature, usually initially room temperature, and then heating the gel material 
until the metal ball begins to descend into the gel medium, thus breaching the integrity of the 
gel.  Other rheological studies are carried out in a rheometer, which studies the flow properties 
of solid-like materials while under an applied force. 
 
1.1 Gel Structure 
 
The gel matrix, an entangled network of fibrous, sheet-like, or rod-like strands, which are 
secondary structures or cables formed from an anisotropic one-dimensional growth of the non-
covalently bound gel molecules, trap solvent molecules within the pores or pockets that result 
from such entanglements.  Images generated by a scanning electron microscopes (SEM image) 
or transmission electron microscopes (TEM image) are generally used to study the morphology 
of such materials.  Scanning electron microscopes magnify surface structures in the micrometer 
range and provide a topographical image for secondary structure analysis.                       
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      1.2  Gelator Design Rationale 
 
The discovery of gelator molecules has predominantly been a circumstance of fortune.  That is 
to say, that the design of novel gelator molecules is limited.  Such limitations are set by the 
confines of the understanding of the gelation phenomenon.  Once a gelator molecule has been 
discovered, however, the rational design of analogues with minor tweaks and modifications, 
and a comprehensive understanding of the properties which support gelation are quickly 
grasped.  It would appear as though an amphiphillic molecular balance must be struck in order 
for a compound to develop gelator properties.  This hydrophobic/hydrophilic duality is 
illustrated in the 2-substituted anthriquinone structures 3-6 (Figure 1.5) synthesized by Chuan-
Feng Chen et al for gel studies15: 
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Figure 1.5 2-substituted anthriquinone structures 3-6                                              
This balance is inherently related to a composition of factors which include molecule-molecule 
interactions as well as solvent-molecule interactions.  Molecule-molecule interactions are such 
that the forces involved pertain only to gelator molecule to gelator molecule interactions, 
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which are necessary for one-dimensional fibrillar assembly.  The solvent-molecule interactions 
assist in a similar fashion, directing the molecular orientations critical for gel formation via 
hydrophobic and/or hydrophillic forces as well as surface tension forces.  The shear multitude 
of factors which must coalesce for gelation to be possible makes it relatively difficult for ab 
initio gelator design.  Through the advancement of gelator research of the past few decades, 
although, the discovery of several classes of gelator compounds provides a platform of 
rationale for molecular design.  Some known classes include: Amino acids (peptides), 
surfactants, amides, ureas, carbohydrates, fatty acids, porphyrin derivatives, nucleobases, 
tripodal compounds, quinolines, etc.  
1.3 Gel Characterization 
 
The characterization and study of these gels via the use of instrumental analysis is quite critical 
to understanding the gel superstructures.  The advancement of gel instrumental analytical 
techniques, such as in instrumentation methods like NMR, scanning electron microscopy, X-ray 
crystallography, and fluorescence study techniques have greatly progressed the understanding 
of gelators and their physical properties as well as the assembly process associated with their 
creation5.  The study of the gel suprastructure as distinguished from the gelator in solution has 
proven very revealing to the gelation process, or the gel-sol transition process, using the 
aforementioned instrumental techniques.  
 
 
8 
 
1.4  UV and Fluorescence Analysis 
 
Yu Fang et al analyzed the gel-sol transition of structures 7-11 (Figure 1.6) through fluorescence 
spectroscopy, by attaching the flourophore naphthalene to an open-chain glucose moiety with 
a hydrazine or extended diamine spacers28.    
S
O
O
NH(CH2)nHN CH2OH
O
OH OH
OH OH
 
Figure 1.6 Glucose based fluorescent gelators 7-11 (n = 0-5)  
 
The fluorescence study revealed an enhanced emission from the gel structure versus the 
emission of the gelator in solution.  This distinction allowed for the group to interrogate the 
processes involved in gel-sol transition.  Such a transition and its reverse glean very illustratively 
the physical processes involved on the molecular level, which can thoroughly be studied by 
examining the emission changes from the fluorophore moiety. The gelator molecule involved in 
the transition process may have incorporated into it a fluorophore which is essential to 
inducing the gelation process or the fluorophore may simply be appended to an existing gel 
molecule, meaning it is not critical to gelation and perhaps effects gelation only slightly.     If, 
when subjected to UV and other fluorescence related frequencies, a gelator does not fluoresce 
significantly or even at all in solution, yet does so when aggregated in the gel matrix form, a 
process dubbed Aggregation Induced Enhanced Emission (AIEE) occurs.  Xiyou Li et al observed 
such varying emissions from gel-sol transitions whilst studying morphologies and gel properties 
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of perylenetetracarboxyilic diimides (PDIs)26.  The perylene functionality, the fluorophore, 
exhibits photoconductive properties which not only assist in structural analysis of gel 
morphologies, but as well may lend applicability in areas such as photoconductive 
nanostructure technology.  As a functionalized gelator, the perylene rings provide the weak 
bonding contribution necessary for intermolecular aggregation in the form of π - π 
stacking.  This, in conjunction with appended hydrophillic polyoxyethylene or long chain 
hydrophobic tails, gave the PDIs the typical amphiphilicity necessary for gelation, as seen in 
compounds 12, 13, and 14 in Figure 1.7: 
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Figure 1.7 Molecular structures of compounds12-14.  
 
The computed optimized molecular structures 12-14 (A-C) are shown below in Figure 1.827:  
   
  
 Figure 1.8  Reprinted with permission from Wu, H.; Xue, L.; Shi, Y.; Chen, Y.;  Li, X.; Langmuir, 2011 
Copyright 2011 American Chemical Society 
 
The absorption/emission data was obtained from 12 and 14 in various organic solvents, the 
details of which are tabulated below.  Compound 13 did not form a gel in any solvent tested. 
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Table 1.1 Gels of compounds 12 and 1326. 
    Compound       Gel I       Gel II       Gel III 
        12   Ethanol:Hexane 
      3.2 mM 
  Toluene:Methanol 
        7.8 mM 
  
        14             Hexane 
       5.0 mM 
 
Figure 1.9 Irradiated with 365nm UV, the fluorescence of gels I, II, and III (with concentrations of 3.2, 
7.8, and 5.0 mM respectively) is displayed. Reprinted with permission from Wu, H.; Xue, L.; Shi, Y.; Chen, 
Y.;  Li, X.; Langmuir, 2011 Copyright 2011 American Chemical Society 
 
From image A in Figure 1.8, one can note that the polyoxyethylene tails are coplanar with the 
PDI ring.  This is because, in compound 12, the phenyl linker between the tail groups and the 
PDI ring allows for this conformation to be possible which, in-turn, likely allows for the proper 
orientational stacking necessary for one dimensional growth—a typical critical criterion for 
gelation to occur.  The absence of this linker in compound 13 likely attributes to its inability to 
gel any of the solvents tested.  Compound 14 as well adopts a non-planar form, but it has 
12 
 
incorporated within it an aliphatic side-chain, which allows for hydrophobic interactions to 
cooperate with the π- π interactions and form gels.  Even the most minute interchromophore 
distance variations are detectable by the very much sensitive techniques of UV-vis and 
fluorescence instrumentation.  For instance, it was inferred by Xiyou Li et al that a significant 
blue shift of 35nm in the absorption spectra obtained26 (Figure 1.10), comparing the PDI 
monomer and a concentrated PDI gel, that a relatively small interplanar distance separated face 
to face stacked PDI molecules.  This led to the conclusion that such intermolecular distances of 
π- π stacked units in the H-aggregates form strong interactions in the ground state and 
therefore absorb at these higher energies.  Fluorescence studies revealed that face-to-face 
stacking occurs in the aggregates formed in gel I.  In consideration of the fact that, in the 
fluorescence spectrum of compound 11 in Figure 1.11, a red shift to 624 nm was observed from 
gel I relative to the monomer in CHCl3, it was inferred by Xiyou Li’s group that an excimer like 
state must be adopted, and there must be interchromophore interactions even in the excited 
state.  A defining feature of Li’s PDIs is that the blue shifts are significantly greater than those 
observed in previously reported literature.  They reasoned that this could be due to minimal 
slippage along the transverse and longitudinal axes, which if larger could perhaps cause a red 
shift.  Their reasoning extended, and they noted that it has been observed that in-plane torsion 
between adjacent PDI molecules causes significant blue shift.  Their reasoning therefore 
culminated in the belief that this particular PDI system exhibited minimal slippages along the 
transverse and longitudinal axes and this must be occurring along with strong in-plane torsion 
and small interplanar distance.  
13 
 
          
Figure 1.10 UV-vis absorption spectra of compound 12 in CHCl3 (Solid), as a dilute gel (Dashed), and as a 
concentrated gel (Dotted). Reprinted with permission from Wu, H.; Xue, L.; Shi, Y.; Chen, Y.;  Li, 
X.; Langmuir, 2011 Copyright 2011 American Chemical Society 
 
A discrepancy in the microstructures of gels I and II is present, although as seen in Figure 1.10, 
similar shifts are observed due to face to face stacking assembly adopted by both gels.  This 
difference, as mentioned, is in the microstructures and Li et al describe the change from 
opaque gel I to the transparent gel II as being attributed to differences in solubility.  Gel I, which 
is in hexane/ethanol 1:1 v/v, forms large aggregates which induce opacity.  The greater 
solubility of 1 in gel II, which is in toluene /methanol, causes the gel to be transparent.  
14 
 
               
Figure 1.11 Fluorescence emmission spectra of compound 12 in CHCl3 (Solid), as a dilute gel (Dashed), 
and as a concentrated gel (Dotted). Reprinted with permission from Wu, H.; Xue, L.; Shi, Y.; Chen, Y.;  Li, 
X.; Langmuir, 2011 Copyright 2011 American Chemical Society 
 
As seen in Figure 1.12, face to face stacking is observed for compound 14 in gel form as 
well.  This inference is based on the observed blue shift of 47 nm relative to the monomer in 
CHCl3.  Further experimentation to assess compound 14’s capacity to maintain a similar shift 
was performed, and it did indeed maintain such a shift down to 10 -7 mol/L in a hexane 
solution.  This suggests that face-to-face stacking occurs at least down to this concentration 
level.  Compound 14 in gel form seems to form J-aggregates.  The maximum at 540 nm and the 
new one forming at 644 are characteristic peaks for PDIs in a coplanar configuration and that 
have π – π interactions.  
15 
 
                           
Figure 1.12 UV-vis spectra of compound 14 in CHCl3 (Solid), Hexane (Dotted), and a dilute gel in hexane 
as a gelling solvent to form gel III (Dashed). Reprinted with permission from Wu, H.; Xue, L.; Shi, Y.; 
Chen, Y.;  Li, X.; Langmuir, 2011 Copyright 2011 American Chemical Society 
 
The absorption spectra, as mentioned above, are significantly different from each other.  To the 
group’s surprise, the emission spectra were not so different for compound 14 in the hexane 
solution versus as a gel in gel III, as seen in Figure 1.13.  This was attributed to a different mode 
of assembly for each.  In the hexane solution, an H-type aggregate formation is occurring 
because excimer-like emissions are observed.  This solution, as observed by the naked eye, is 
red in color.  The fluorescence of gel III shows an emissions signature characteristic to that of a 
J-aggregate assembly.  This solution is black. 
16 
 
                          
Figure 1.13  Fluorescence spectra of compound 14 in CHCl3 (Solid), Hexane (Dotted), and a dilute gel in 
hexane as a gelling solvent to form gel III (Dashed). Reprinted with permission from Wu, H.; Xue, L.; Shi, 
Y.; Chen, Y.;  Li, X.; Langmuir, 2011 Copyright 2011 American Chemical Society  
 
 
Li et al developed a “speculated” microstructure for each of the gels I, II, and III.  These 
structures were determined in-large part due to the fluorescence emission and UV-vis 
obtained.  Additional characterizations were performed, including X-ray diffraction (XRD) and 
atomic force microscopy (AFM) measurements. For compound 12 gel 1, the intermolecular 
orientations are face to face stacked.  It was speculated that the primary contributing source 
for intermolecular non-covalent bonding was the π – π interactions from the PDI moiety.  The 
hydrophobic side-chains did not pack with high order due to bending and tangling, and small in-
plane torsion was also attributed to gel I.    
 The “speculated” microstructures are presented below in Figure 1.14: 
17 
 
 
 
 
Figure 1.14  Speculated microstructures of gels formed by compounds 12 and 14. Reprinted with 
permission from Wu, H.; Xue, L.; Shi, Y.; Chen, Y.;  Li, X.; Langmuir, 2011 Copyright 2011 American 
Chemical Society 
 
1.5  Probing the Mode of Gelator Assembly   
 
 The mode of assembly/disassembly which is involved in the aggregative formation or 
disruption of fibrils of gels may parallel the self-association of β-Amyloid plaque formation or 
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potential disruption, respectively, in the brain of Alzheimer afflicted persons.  β-Amyloid plaque 
formation and brain deposition, which in-turn leads to brain lesions, is a major hallmark of 
Alzheimer’s disease, and perhaps the primary culprit for the onset of this degenerative disease.  
Santiago V. Luis et al set out to probe a gel systems self-assembly pathways and load capacity 
under the effects of naproxen (NPX)27, a non-steroidal anti-inflammatory drug (NSAID), in an 
effort to simulate how such a drug may affect β-Amyloid aggregate formation.  Research has 
suggested that such an NSAID may interact with the amyloid plaques or at least the precursors 
thereof and inhibit their formation.  The analysis of such aggregative action was performed by 
Luis and his group using peptidomimetic cyclophane compound 16, with naproxen embedded 
within its gel matrix:  
 
                       
H3CO
COOH
HNNH
NH HN OO
15  (NPX)                                                            16  
 
Figure 1.15  Chemical structures of Naproxen (NPX) and cyclophane compound 16 
 
        
With an NSAID such as naproxen embedded within the gel matrix, from a biomedical context 
regarding, for instance β-amyloid fibril disruption, time resolved fluorescence spectroscopy 
could be used effectively to elucidate the interactions the chromophore has with the gel 
assembly, as described by Luis et al.  The integrity of the gels formed by 16, which had varying 
concentrations of NPX incorporated within, was assessed by measuring the gel melting 
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temperatures (Tg).  The observed melting trends indicated that the higher the NPX load was, 
the weaker the gel assembly (Lower Tg) .  In table 1.2, R represents the degree of linear 
correlation. 
 
Table 1.2  The gradient melting temperature of gelator compound 16 loaded with NPX27 
16 
(mg/mL) 
NPX 
(M) 
Tg 
(0C) 
R 
4 0.0 50.9 + 0.7 0.9988 
4 4.0 x 10-4 49.1 + 0.4 0.9991 
4 2.5 x 10-3 47.7 + 0.7 0.9983 
 
 
 
At this juncture it was clear that an effect, specifically a weakening one, had occurred from the 
addition of NPX, yet when absorption and steady-state fluorescence spectroscopy were 
performed, no notable spectroscopic changes had taken place from the NPX monomer in 
solution and in the gels.  This compelled the group to explore other fluorescence techniques 
which would help in the interrogation of system integrity differences.  Therefore, time 
correlated single photon counting (TCSPC), a time resolved fluorescence technique which 
correlates minute distinctions of fluorescent species in different environments.  Absorption, 
excitation, and emission results were fit into the model below, which was calculated by using 
the following multiexponential equation (eq. 1.1) of individual decays (i): 
 
equation 1.1:                                      F(t) = ∑ αi 
(-t/τ
i
) 
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The following (Figure 1.16) illustrates the normalized spectra of NPX in toluene and in the gel 
state. 
              
Figure 1.16  Normalized spectra of NPX in toluene and in the gel state. Permission license No. 
 
2864890165106 
 
 
The i components, which represent the various fluorescence lifetimes, are summated in the 
variable τi which represents the individual fluorescence lifetime, and αi which is a 
representation of its contribution to the total signal.  The degree to which the fluorescence 
decay times fit the multiexponential results properly is designated χ2.  In accordance with 
previous data concerning NPX in various organic solvents, the monoexponential fit for its 
fluorescence decay time in toluene was χ2 = 1.07 where τ = 7.38ns {26}.  The monoexponential 
decay for 16 in the gel state did not exhibit a good fit, although.  When the biexponential, 
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however, was applied to the decay function, a more precise fit was observed.  The observed 
lifetimes of the two contributors τ1 and τ2 were 7.89ns and 1.46ns, respectively.  The variable τ1 
contributed to 97.3% of the signal, whereas τ2 contributed to 2.7%.  It was hypothesized by Luis 
et al that the larger component of the fluorescence lifetime can be attributed to the decay of 
NPX that is not interacting with the gel matrix, and that the smaller lifetime may correspond to 
NPX which is in the vicinity of gel fibers, and thus interacting with the architectural assemblage 
composed of 16.  To support this theory, gradient increase of the gelator molecule 
concentration was applied, which revealed that the smaller lifetime component gradually 
increased with increasing concentration.  The logic was such that if the gelator molecule 
concentration increased, the interactions between NPX and 16 would increase proportionately 
due to its greater prevalence, thusly increasing the lifetime of τ2.  This in fact was observed, as 
tabulated in the following table: 
 
Table 1.3  Gels of gelator 16 at various concentrations irradiated with 350 nm UV with recorded 
fluorescence lifetimes27 
16 (mg/mL) τ1  (ns) α1 (%) τ2 (ns) α2 (%) χ
2 
0 7.38 100 - - 1.07 
4.0 7.89 97.3 1.46 2.7 1.11 
7.3 8.27 95.1 1.34 4.9 1.24 
10.3 8.30 93.0 1.16 7.0 1.17 
 
 
The UV-vis absorption and fluorescence analyses performed by Luis et al did not show any 
significant distinctions in spectral results when steady state and conventional spectroscopic 
techniques were applied, yet when time resolved fluorescence spectroscopy was applied, 
distinctions between emission and excitation spectra were observed in normalized models.    
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Fluorescent probing, as past research has shown, can assist in elucidating the mechanism of 
action which is involved in gel formation, but there are sometimes external or internal stimuli 
that assist in architectural assembly.  The mode of aggregation involved in these cases is 
sometimes not fully understood, yet our comprehension of how it occurs is rapidly growing.  It 
has been known for some time now that impregnating a potential gel system with metal salts 
may either buttress or rigidify a gel, but may also lead to gel formation, where such formation 
would have otherwise not occurred.  Additionally, thermal treatment or ultrasound irradiation 
may assist in gelation by providing the necessary energy to overcome certain barriers 
associated with the intermolecular orientations needed for one dimensional growth.  
Masamichi Yamanaka and Hiromitsu Fujii explored these effects21 with a gel system which uses 
tris-urea LMWG 17 in Figure 1.17.   
                 
O
O
O
NH
HN
N
H
O NH
C8H17
N
H
O
C8H17
O
HN
C8H17
17  
 
Figure 1.17  Tris-urea LMWG 17. 
 
 
Compound 17 has the property of C3 symmetry, which is derived from functionalizing 
phloroglucinol.  Initially, 4-flouronitrobenzene was reacted with phloroglucinol via nucleophilic 
aromatic substitution to give a tris-nitro compound.  The nitro groups were subsequently 
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reduced using hydrogen with palladium on carbon, and then this compound was reacted excess 
octylisocyanate, which afforded the white solid product of 17, as illustrated in Figure 1.17.  It 
should be noted that this is a highly versatile synthetic route, and alterations can easily be 
made to explore the use of other substituents on phloroglucinol and on the substituted 
aromatic ring.   
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Scheme 1.1  Synthesis of tris-urea 15. 
 
 
Four chloroalkane solvents were tested for the gel properties of 15 in each under various 
conditions.  These solvents were: dichloromethane, chloroform, 1,1,2-trichloroethane, and 
1,1,2,2-tetrachloroethane.  The aforementioned treatments, which include thermal treatment 
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via heating and cooling to either room temperature of flash cooling using an ice bath, 
ultrasound irradiation using a sonicator, and/or metal salt doping were then applied using each 
of these solvents. Comparisons were made and system properties inferred from the gel 
responses to the internal and external stimuli applied.  Compound 17 only formed a full gel in 
1,1,2-trichloroethane with thermal treatment, and a partial gel in 1,1,2,2-tetrachloroethane.  To 
test how a metal salt, namely CuBr2, would affect gelation, a stoichiometric equivalent was 
added to each the 1,1,2-trichloroethane and the 1,1,2,2-tetrachloroethane, as seen in Figure 
1.19.  Not only did this addition transform the partial gel of tetrachloroethane into a full gelator 
with an MGC of 5mM, but it as well decreased the MGC of the trichloroethane gel from 10mM 
to 5mM when thermally treated (Table 1.4).   
 
 
       
Figure 1.18  Gel experimental results depicted in which mixtures of of the four previously mentioned 
chloroalkanes, (a) CH2Cl2, (b) CHCl3, (c) 1,1,2-trichloroethane, and (d) 1,1,2,2-tetrachloroethane and tris-
urea gel compound 17. Reprinted with permission from Yamanaka, M.; Fujii, H.; J. Org. Chem., 2009, 74, 
5390–5394. Copyright 2009 American Chemical Society 
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Figure 1.19  Photographs acquired by Fujii et al of CuBr2 doped gels of 17 along with the standard 
chloroalkanes (a) CH2Cl2, (b) CHCl3, (c) 1,1,2-trichloroethane, and (d) 1,1,2,2-tetrachloroethane. 
Reprinted with permission from Yamanaka, M.; Fujii, H.; J. Org. Chem., 2009, 74, 5390–5394. Copyright 
2009 American Chemical Society 
 
 
Table 1.4  Resultant properties of gels formed with 15 under thermal treatment conditions.21  
additive CH2Cl2 CHCl3 1,1,2-
trichloroethane 
1,1,2,2-
tetrachloroethane 
none I I G (10) PG 
CuBr2 I I G (5) G (5) 
Key:  Gel results with Tris-urea gelator 17 having concentrations of up to 25 mM, where: G = gel; PG = 
partial gel; I = insoluble suspension.  The critical gelation concentrations are denoted as (mM) 
               
 
Morphological transformations were as well observed in the SEM images of 1,1,2-
trichloroethane gels (Figure 1.20), which exhibited a fibrous entanglement in the absence of 
CuBr2, and spherical particles in the presence of the metal salt.  This suggests that the modes of 
assembly for each system are different.  An SEM image was as well acquired for the partial gel 
of 17 formed in 1,1,2,2-tetrachloroethane in the presence and absence of CuBr2.  Notably 
thinner fibrous aggregates formed in the metal salt loaded medium.   
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Figure 1.20  Xerogel images of (a) 1,1,2-trichloroethane gel with 17; (b) 1,1,2,2-tetrachloroethane partial 
gel of 17; (a) 1,1,2-trichloroethane gel with 17 and CuBr2; and (d) 1,1,2,2-tetrachloroethane gel of 17 and 
CuBr2. Reprinted with permission from Yamanaka, M.; Fujii, H.; J. Org. Chem., 2009, 74, 5390–5394. 
Copyright 2009 American Chemical Society 
 
 
Under the influence of ultrasound irradiation gelation may be induced where it would 
otherwise have not occurred, as was the case with thermal treatment of compound 17.  The  
 
Table 1.5  Resultant properties of gels formed with 17 under ultrasound irradiation treatment 
conditions21 
additive CH2Cl2 CHCl3 1,1,2-
trichloroethane 
1,1,2,2-
tetrachloroethane 
none I G (15) I G (5) 
CuBr2 I G (5) I G (5) 
BiCl3 G (15) PG I G (20) 
Y(NO3)3 PG G (10) I I 
Key:  Gel results with Tris-urea gelator 17 having concentrations of up to 25 mM, where: G = gel; PG = 
partial gel; I = insoluble suspension.  The critical gelation concentrations are denoted as (mM) 
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following table summarizes the results where sonication only and sonication plus metal salt 
incorporation were done.   
 
 
 
1.6  Tuning Gel Morphology and Rheological Properties With Internal and 
External Stimuli 
 
 
                   
This study performed by Yamanaka and Fujii demonstrates how the tweaking of external and 
internal stimuli can affect gelation, particularly through thermal heating and cooling, ultrasound 
sonication, and metal salt/ligand doping.  Cheng Wang et al have experimented with tuning 
techniques which trigger reversible gel-sol transitions under the influence of photo induced 
isomerization and redox chemistry using organogelators based on tetrathiofulvalene and 
azobenzene groups.  Photoreactive groups such as azobenzene and stilbene have been 
incorporated into LMWGs with the intent for such groups to trigger gel-sol transitions11,12.  It is 
specifically the tetrathiofulvalene moiety which is electroactive and responds to redox 
conditions whether they are chemical or electrochemical.  The multistimuli responsive gelator 
18 has incorporated within it such functionalities by rationale design to exploit the 
aforementioned properties.   
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Figure 1.21  Tetrathiofulvalene (TTF) compound 18. Reprinted with permission from: Wang, X.; Xing, L.; 
Cao, W.; Li, X.; Chen, B.; Tung, C.; Wu, L.; Langmuir. Copyright 2011 American Chemical Society 
 
 
 
The oxidation state of the TTF moiety can reversibly change to TTF.+ radical cations or TTF2+ 
dications when redox conditions are applied.  A conformational change is triggered by 
irradiating compound 18 with the proper wavelength of electromagnetic energy, which causes 
cis-trans isomerization.  Simply incorporating the stimuli responsive functionalities into the gel 
molecule, however, will not necessarily provide the crucial balance that must be achieved in  
 
Table 1.6.  Gelation results for compound 18.11 
solvent gelation examination 
CH2Cl2/ CH3OH  (3/1, v/v) G (4.0 mg/mL) 
CHCl3/ CH3OH  (3/1, v/v) G (4.0 mg/mL) 
CH2Cl2/ n-hexane  (1/1, v/v) G (4.0 mg/mL) 
CHCl3/ n-hexane  (1/1, v/v) G (4.0 mg/mL) 
THF G (4.0 mg/mL) 
toluene G (4.0 mg/mL) 
CH2Cl2/ CHCl3 S 
1,2-dichloroethane, CCl4 P 
n-hexane, cyclohexane, methanol, ethanol, 
DMF, DMSO, Acetone, CH3CN, ethyl acetate 
I 
Key: G = gel, where MGCs are presented in mg/mL; S = soluble; P = precipitate; I = insoluble 
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order to construct a functional gelator molecule.  This balance can be manipulated by attaching 
functional groups which will either decrease or increase the overall LogP value of the molecule, 
or in other words, the overall polarity.  This was accomplished by tacking cholesterol to each 
end of the gel molecule.  The gelation results are summarized in table 1.6.  When analyzed in 
the gel form, compound 18 has a broad absorption band in the vicinity of 360nm, and it was 
observed that this broad band had diminished over time as another band had intensified in the 
range of 450nm.  The band at 360nm can be assigned to the trans form of the azobenzene 
portion of 18, and the emerging one at 450nm is assigned to the cis form.  Wang et al reported 
that HPLC results indicated that the composition of the solution at t0 was 81.6% trans and 
18.4% cis.  As seen in the below florescence spectrum, a photostationary state  
 
 
Figure 1.22  Left: The absorption spectra of TTF gelator 18 irradiated at 365nm for varying durations.  
Right: The absorption spectra for gelator 18 when irradiated with UV light, initially for 50 s, and then 
subsequently at varying times.  The concentrations of each were 1.0 × 10-5 M in CH2Cl2/CH3OH (3:1).  The 
insets emphasize the 400-600 nm range.  Reprinted with permission from: Wang, X.; Xing, L.; Cao, W.; Li, 
X.; Chen, B.; Tung, C.; Wu, L.; Langmuir. Copyright 2011 American Chemical Society 
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spectrum was acquired for 50s under UV irradiation conditions, and the resultant composition 
at this time was 96.8% cis and 3.2% trans.  It was reported that continued irradiation of the 
sample with visible light energy reverted the samples composition to a predominating trans 
isomer presence.  Interestingly, the cholesterol moiety not only made a hydrophobic 
contribution to the gel molecule, thusly helping to balance the overall polarity, but it also likely 
imparted chiral growth of the thin fiber formations.  This is suggested by analysis of the CD 
spectra obtained by the group, which showed positive CD signals at 368 and 384nm.  These 
signals gradually disappeared as the gel approached its solution phase through the application 
of heat. 
 
 
Figure 1.23  The CD spectra gelator 18 with a concentration of 8.0 mg/mL in CH2Cl2 (3/1, v/v) in: 1) 
Solution; and 2) the resultant gel and subsequent UV spectra thereof at 20, 40, and 60 s respectively.  
Reprinted with permission from: Wang, X.; Xing, L.; Cao, W.; Li, X.; Chen, B.; Tung, C.; Wu, L.; Langmuir. 
Copyright 2011 American Chemical Society 
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1.7  Hydrogelators as drug-delivery devices 
Hydrogelator disassembly or the reverse under the influence of chemical stimuli such as 
enzymes for the purpose of drug delivery has been explored by George John et al61.  Within the 
developing technology of hydrogelator drug delivery, LMWGs provide some distinct advantages 
to the currently more prevalent mode which uses polymer hydrogels.  These include: possible 
lower toxicity, increased biodegradability, and also the property of thermoreversability which is 
a more prominent LMWG feature.  A variety of delivery platforms have been experimented 
with.  One process simply entraps a hydrophobic drug within the gel matrix as seen in 
mechanism of action A in Figure 1.24 below.  Another more rare condition is when the gel 
molecule is itself is the active therapeutic agent, in which case its capacity to gelate water is 
coincidence and not by design.  And perhaps the most rational process, at least from the design 
standpoint, is to simply attach a therapeutic agent covalently to a known gelator using an 
enzyme-sensitive spacer.   
 
Figure 1.24  Various hydrogelator drug delivery models A-C.42   Permission license No. 2864891090877 
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One of the most alluring aspects of this form of enzymatically triggered drug delivery is that 
specific locations in the body can be triggered for such release.  George John et al prepared a 
prodrug amphiphilic gel assembly which used the antipyretic acetaminophen.  Studies were as 
well conducted to demonstrate this gelator’s ability to host yet another therapeutic agent, 
namely curcumin, which is a known chemopreventative drug and is as well used as an anti-
inflammatory agent.  The synthesis of these hydrogelator amphiphiles is shown below starting 
from acetaminophen in Scheme 1.2: 
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Scheme 1.2  Conditions for amphiphiles and bolaamphiphiles 19-24 from precursor acetaminophen: (i) 
dodecanoic acid, dicyclohexylcarbodimide (DCC), dimethylaminopyridine (DMAP), anhydrous 
tetrahydrofuran (THF), rt, 24 h. (ii) a,ω-dicarboxylic acid (0.5 equiv.), DCC, DMAP, dry THF rt, 48 h. (iii) a, 
ω -dicarboxylic acid (1.2 equiv.), DCC, DMAP, dry THF, rt, 24 h. (iv) 6-bromomethylhexanoate, K2CO3, dry 
THF, reflux, 12 h. (v) NaOH, MeOH, rt, 12 h 
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The above design is based not only on the synthesis of amphiphiles, but also bolaamphiphiles 
which have hydrophilic polar groups attached at each end of a hydrophobic chain linker.  By 
design, upon degradation, the gel does not produce toxic fragments or byproducts which could 
be considered harmful.  This and several other factors must be evaluated as potential health 
hazards.  As the acetaminophen is released, only a long-chain fatty acid accompanies the 
disintegration, an extremely important consideration for any such system. 
 
 
1.8 Monosaccharide Based Gelators   
 
Carbohydrate based gelators, namely monosaccharide based gel molecules, are of great 
importance to efforts in understanding gel systems102-104.  Predictable hydrogen bond based 
networks, which can be formed by the many free –OH groups in monosaccharides are potential 
frameworks which could lead to gelation of various solvents.  Accessibility to these hydrogen 
bond donors, abundance of them, and hydrophobic balance are three factors which are more 
easily controlled when dealing with monosaccharide systems, making them ideal candidates for 
designing gelators.  For instance, Luboradzki et al performed analytical experiments on a 
tunable gelator system comprised of two different monosaccharides 25 and 26-28 (Figure 1.25), 
exploiting the three free –OH groups as hydrogen bond donors/acceptors for gel matrix 
assembly105-109.      
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Scheme 1.25  Glucofuranose monosaccharide gelators 25-28.  Varying amounts of 26, 27, or 28 added to 
25 to ‘tune’ the gel assembly 
 
 The R groups projecting off of the dioxolane groups in compounds 26-28 help to modulate the 
hydrophobic chain length, thus helping establish the proper amphiphilicity necessary for 
gelation.  In the case of a two component system such as this, adding a second molecule to the 
system may be critical for molecular assembly in an anisotropic fashion.  In the case of 
Luboradzki et al, this addition only modified the gel structure, albeit in a fashion which in some 
cases enhanced the gel structure 
Conclusion 
The design of novel gelator molecules is limited currently, although, the discovery of the 
previously mentioned classes of gelator compounds does provides a platform of rationale for 
molecular design.  Understanding the assembly process through the use of instrumentation and 
molecular probes gains the necessary insight to work toward such a goal.  With every new 
gelator molecule synthesized, a step toward gelator design is taken.  Various LMWG molecules 
were explored to illustrate the capacity of these systems to be used in applications such as drug 
delivery and other various stimuli responsive uses. 
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Chapter II. A Glucose Based 4,6-O-Protected Diphenyl Ketal System 
 
Abstract 
 
Within the field of supramolecular chemistry, low molecular weight gelators are an important 
new class of compounds which are of special interest because of their wide scope of significant 
applications as advanced materials. Past and current research performed by the Wang group 
indicates that analogues of various 4,6-acetals of either 1-deoxy or 1-methoxy glucopyranosides 
form stable gels in organic, aqueous, and organic/aqueous solvents at various concentrations. 
To understand the structural requirements of such analogous sugar-headgroups, a series of 4,6-
diphenyl acetal derivatives of glucose were synthesized, and their respective gel properties 
were analyzed in order to understand the structural influence of these novel molecules toward 
supramolecular gelation. The synthesis and characterization of these new compounds are 
presented in this chapter, as well as a detailed analysis of how such a series with an abundance 
of aromatic moieties promotes π-π stacking, and thus obstructs or contributes to gel matrix 
formation. 
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Introduction 
 
Glucose based low molecular weight gelator (LMWG) systems have previously been explored by 
few to reveal that such molecules are indeed efficient and promising gelators1.  This class of 
carbohydrate based molecules is profoundly versatile, resulting from their structures2,3.  The 
key non-covalent forces which are involved in the formation of the supramolecular assemblies 
are: π-π interactions, Van der Waals interactions, and hydrogen donor/acceptor interactions4.  
Sugar based LMWGs may easily be incorporated with π systems, long aliphatic chains, and 
various other functional groups which serve to achieve a specifically desired amphiphilic 
equilibrium. Additionally, exploitation of pre-existing hydroxyl groups for the potential 
formation of hydrogen bonding arrays makes these systems attractive as ideal candidates for 
having inherent or at least potential gel properties. Carbohydrate based low molecular weight 
gelators not only exemplify a great capacity to form gels efficiently, but as well show great 
promise as biocompatible molecules.  One such factor which is sometimes significantly 
important is the chirality which is inherent to glucose derived molecules5.  The assemblies of 
gelators, which have inherent chirality, often form with helical winding.  This inherent 
molecular chirality confers the observed helices in some of the macrostructures of the systems 
there-of.  Saccharide molecules are functional heterocycles with free hydroxyl sites ready for 
selective functionalization as well.  Sugars are a class of compounds which are versatile when it 
comes to functionalization, and the established platform of having a thorough understanding of 
selective functionalization provides pre-established routes to afford gel molecules.  Das et al 
performed the synthesis of 4,6-O-protected N-glycosylamines 1-3 starting from simple D-
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glucose (Figure 2.1) and subsequently anomerically appended with either iodine treated 2-
aminopyridine 4 or 3-amino-2-chloropyridine 5 as seen in Figure 2.113,14.  Multiple spectral 
analysis techniques were employed to explore interactions which were taking place that 
contributed to gel formation, which included π-π stacking and hydrogen bonding.  It was also  
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Figure 2.1  D-glucose 
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Scheme 2.1  Synthesis of N-glycolysalmines 1-3: (i) 2-aminopyridine 4, I2, DMF, rt, 50%;  (ii)  2-
aminopyridine, 5-iodo-2-aminopyridine 5, ethanol, rt, 23-69%;  (iii) 3-amino-2-chloropyridine 6, ethanol, 
rt, 60-71%.  These reagents produced compounds 7-15 when reacted with the respective 
glucose derivative 
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noted by Das’s group that dipole dipole interactions were as well responsible for holding 
together the gel structure, along with other ‘modes of interaction’ as revealed by 
computational methods15,16.  Utilizing simple monosaccharide molecules such as glucose as 
starting materials, the Wang group synthesizes gelator molecules and performs thorough 
analyses which prove instrumental to our understanding of such systems. 
Past and current research performed by the Wang group reveals that analogues of various 4,6-
acetals of either 1-deoxy or 1-methoxy glucopyranosides, such as those derived from 
headgroup 16, form stable gels in organic, aqueous, and organic/aqueous solvents at varying 
concentrations.  The derivatization of 16 entails either the selective functionalization of one of 
two free –OH groups to produce a “C2” or “C3” monomer, or the dual functionalization of each 
available –OH producing the dimeric form of analogue.  The functional groups are typically 
esters, ureas, carbamates, or amides and they are usually terminated with a moderate to long 
hydrophobic tail.  In the case of the monomers, either the C2 or C3 –OH remains 
unfunctionalized and may therefore be available for hydrogen bond donation.   
OO
HO
OH
O
OMe
16  
Figure 2.2  A previously synthesized headgroup from which several analogues were synthesized that 
have proven to be effective gelators 
 
The hydrogen bond stacking array is depicted Figure 2.3, where in the instance of this particular 
illustration, the C2 –OH is functionalized.  Additionally, the 4,6-protecting group is aligned in 
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such a way that π-π stacking is permitted and thus as well contributes to the 1-dimensional, 
anisotropic growth. 
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Hydrogen bond
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Hydrogen bond
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Figure 2.3 Representative hydrogen bonding array of glucose derived gelators from 16 
 
Previous research revealed that analogues 17-19 (A-C), which are derivatives of 16 that housed 
terminal alkynyl esters, were found to be good gelators in a variety of organic, aqueous, and 
organic/aqueous solvent mixtures (Scheme 14).  The Wang group set out to understand the 
structural requirements which instilled these terminal acetylene containing glucose derivatives 
with gelation abilities.  It was reasoned, regarding the structural requirements of the 
hydrophobic tails, that high packing order which may accompany analogues containing long 
aliphatic chains sometimes causes crystallization rather than a loosely held gel matrix structure.  
It was conjectured that the terminal acetylene functionalities of 17-19 disrupted the packing 
order of the gelator molecules, which hindered precipitation and allowed for the architectural 
assemblage needed to form the observed stable gels.   
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Scheme 2.2  The terminal alkynyl esters 17-19 (5-7 carbon length A-C) which were found to be good 
gelators various organic and organic/aqueous solutions  
 
 
Results and Discussions 
 
Compounds 16 and 20 are precursors to several known gelators which include esters, amides, 
carbamates, and ureas.  A new series was analyzed for its gelator properties and probed to 
reveal any disparities in structural requirements regarding the 4,6-O position of the glucose and 
glucosamine analogues.  Assessment of trends correlated with minor structural modifications of  
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Figure 2.4  Juxtaposition of compounds 16 and 20, differing structurally at the C2 position 
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the sugar headgroups or functionalities thereof, especially the 4,6-protecting group or 
anomeric appendage, has provided great insight into the structural requirements of multiple 
series of glucose-based gelators based on the general structure of 16 and 20.    To further 
investigate the structural requirements of such analogous sugar-headgroups and their 
derivatives, a series of 4,6-diphenyl acetal derivatives of glucose were synthesized from 38 in 
hopes of understanding the structural influence of these novel molecules toward 
supramolecular gelation.  The structural requirements regarding the hydrophillic tails and 
anomeric functionalities had been thoroughly explored and, as seen in Figure 2.5, the diphenyl 
acetal as compared to a benzylidene acetal was predicted to have interesting and sustained 
gelation properties, due to its having an extra π system for building π stacking arrays which 
could provide more non-covalent bonding opportunities for building the gel matrix to exploit.   
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         16                                                         21  
Figure 2.5 Headgroups 16 and 21, with a 4,6-acetal modification on molecule 21 
The synthesis of 21 begins with the starting material benzophenone 22, as seen in Scheme 2.3.   
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Scheme 2.3  Synthesis of diphenyl gelator headgroup 21 
 
Literature reports for the synthesis of 23 included various conditions using organometallic 
salts17, yet a simpler approach was desired, whilst maintaining a relatively high yield.  The 
synthesis that was employed uses 3 equivalents of trimethylorthoformate in the presence of 10 
mol% p-TsOH dissolved within methanol.  A simple work-up using powdered sodium 
bicarbonate to quench the reaction, followed by filtration using cold dichloromethane provides 
pure product.  This scheme is continued by subsequently 4,6-O-protecting methyl-α-D-
glucopyranoside with dimethoxy acetal 23 to afford 4,6-diphenyl acetal glucopyranoside 21.  
The esterifications performed on headgroup 21 (Scheme 19) typically yielded three products: 
the C2 and C3 monomers (analogues of type B and C, respectively), and diester form (analogues 
of type A) which has both –OHs functionalized.  For the purpose of gelation studies, only the C2 
and Diester forms are reported (Table 2.1) because the C3 formation wasn’t consistently 
sufficient in producing enough material for analysis and testing, or was perhaps not even 
isolated at all.   
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Scheme 2.4  Synthesis of ester analogues of monomeric forms B and C, and dimeric form A 
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Table 2.1 Gelation Results of the Diester Series 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
25A 31 % I S S P P 
26A 8 % I I P P P 
27A 13 % I S P P P 
28A 17 % I S S P P 
29A 20 % I S I I I 
30A 11 % I S I P P 
31A 5 % I I P P P 
32A 14 % I I S P P 
33A 10 % I I S P P 
34A 10 % I I S P P 
35A N/A - - - - - 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
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Table 2.2 Gelation Results of the C2 Monoester Series 
 
Yield Water Hexane EtOH Water:EtOH 
2:1 
Water:DMSO 
2:1 
25B 13 % I I S P P 
26B 29 % I P P P U (20) 
27B 42 % I S P P P 
28B 43 % I I S P P 
29B 40 % I I S P P 
30B 38 % I I P P P 
31B 30 % I S I P U (20) 
32B 19 % I I S P P 
33B 11 % I I S P P 
34B 55 % I I S P P 
35B 64 % I I S I S 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
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Considering that none of the esters from the diester or monoester series were able to form 
gels, the headgroup was tested to see if the additional –OH group would assist in gelation.  At 
this point, it was evident that the absence of a hydrophobic tail, and with the introduction of 
yet another H-bond donor, the necessary amphiphilic equilibrium for gelation may be 
reestablished. 
 
 
 
Table 2.3  Gelation results of glucose derived headgroup 
 
Compound 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
 
84 % P I S G (10.5) G (23) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
The 4,6-diphenyl  ester series did not prove to effectively gelate solvents of either aqueous or 
organic compostion.  It was conjectured that too high of a packing order was occurring due to 
oversaturation of the molecule with aromatic and aliphatic substituents which lead to strong 
intermolecular interactions.  These groups either likely led to a packing order which was too 
high due to all of the π-π bonding contributions or perhaps was due to a packing order which 
was too low, due to disruption from the bulky 4,6 protecting group.  An X-ray crystal structure 
was obtained for compound 35B, which in addition to the aromatic moieties at the 4,6 position 
OO
HO
OH
O
OMe
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has a naphthyl appendage at the C2 position.  The molecular stacking array seen below (Figure 
2.6) in the crystal lattice firmly suggests a packing order which was too high to form the 
necessary weaker bond interactions for gel matrix formation.   
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Figure 2.6 Rendered crystal structure for compound 35B 
Unit Cell of Compound 35B 
 
 
35
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From headgroup 21, carbamate analogues were synthesized.  The provision of yet another 
hydrogen bond donor was expected to have desirable effects regarding such a series’ ability to 
form gels.  The synthesis follows in Scheme 20: 
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Scheme 2.5  Synthesis of carbamates analogues 
 
this series was not producing efficient gelators based on glucose.  To more thoroughly probe 
the gelling capacity for the various analogues of the 4,6-diphenyl series, amide based LMWGs 
were synthesized.  Although the esters did not prove to be efficient gelators, it was predicted 
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Table 2.3  Carbamate gel results 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
36 43 % I I S P P 
37 15 % I I S I I 
38 13 % I I S P P 
39 13 % I I S P P 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
As the synthesis of these various carbamates analogues progressed, it was becoming clear that 
 that the additional hydrogen bonding sites afforded by amides and carbamates may provide a 
packing order suited for gel matrix formation.  The general synthesis for each gelator type is 
presented below in Scheme 2.6: 
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Scheme 2.6  Syntesis of N-acetyl glucosamine derived amides and ureas 
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Scheme 2.7 Synthesis of amide analogues 
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Table 2.4  Amide Gelator Results 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
44 88 % I I S P U (20) 
45 73 % I I S G (6.3) G (13.5) 
46 40 % I I S U (20) G (5) 
47 37 % I I S P G (10) 
48 85 % I I U (21) I P 
49 77 % I I S P P 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
As predicted, the additional –H bond donor site from the –NH bestowed some gelation 
properties to this system, although not as much as was observed with previous systems.  This 
would suggest that even though some gel properties are restored when adding an –NH bond 
donor from amide derivatives, but that the diphenyl group was still somehow disrupting 
gelation.  To further investigate the effects of having an amide or amino group directly attached 
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to the C2 of the glucosamine derivative, headgroup 43 and it’s precursor, -N-acetyl glucosamine 
derivative 42, were tested for their gelation capabilities.  Both were able to form stable gels in 
2:1 water:DMSO, indicating that a shift toward hydrophilicity imparts a greater gelling capacity 
to this system. 
 
Table 2.5  Glucosamine Headgroup Gel Results 
 
Compound 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
 
72 % I I S P G (23) 
 
- I I S P G (8.7) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
Conclusions 
From investigation of the gelation results of the glucosamine derived headgroup, it is apparent 
that the additional phenyl ring makes this series too hydrophobic to gelate solvents effectively.  
As revealed by both the free amine and N-acetyl form of the headgroup, a shift toward greater 
O
NH
OMe
O
O
HO
O
O
NH2
OMe
O
O
HO
60 
 
hydrophilicity restores gelling capacity.  In the ester series, aromatic substituents, in addition to 
the extra phenyl group of the diphenyl ketal, likely led to oversaturation of π interactions, 
disallowing gel matrix formation, favoring precipitation.  The carbamate analogues were 
expected to form gels in some solvents because of the additional –NH present for hydrogen 
bonding, yet did not. This as well leads to the conclusion that the additional aromatic ring 
disrupted, rather than encouraged gel formation.  For the amides, short length hydrophobic 
tails were tolerated; this is due to the enhanced hydrogen bonding from the amide functional 
group.   
 
Experimental section  
 
Synthesis of benzophenone dimethyl acetal 23:  To a 500 mL round bottomed flask, 16.12 g 
(88.5 mmol) of benzophenone was added and dissolved within 125 mL of MeOH and stirred at 
room temperature.  To this stirred solution, 29 mL (3 equivalents) of trimethyl orthofromate 
was added along with 10 mol% (1.68 g) of p-toluene sulfonic acid.  Another 3 equivalents of 
trimethyl orthoformate was additionally added 5 hours after the initial starting time.  This 
reaction mixture was subsequently brought to 700C and refluxed for 46 hrs, the reaction was 
neutralized with powdered sodium bicarbonate and then filtered and washed with DCM.  The 
reaction solvent was evaporated affording the pure solid product.  Yield:  92%; 1H NMR (400 
MHz, Chloroform-d) δ 7.50 (s, 3H), 7.29 (dd, 5H), 7.27 – 7.12 (m, 1H), 3.13 (d, J = 0.9 Hz, 5H). 
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Synthesis of 4,6-O-diphenyl-methyl-α-glucopyranoside 21:  To a 500 mL round bottomed flask, 
5.13 g (26.4 mmol) of methyl-α-glucopyranside 24 was added and dissolved within 60 mL of 
DMF and stirred at room temperature.  To this solution, 10.67 (2.25 equivalents) of 
benzophenone dimethyl acetal 23 and the reaction mixture was brought to 1000C.  To this hot 
solution, 20 mol% of p-toluene sulfonic acid was added and the reaction mixture stirred for 21 
hours, after which time stirring was discontinued.  The flask was then adapted to a rotary 
evaporator and the methanol byproduct was removed to push the reaction toward completion.  
Added powdered sodium bicarbonate to this solution to neutralize acid, and then subsequently 
filtered.  The solvent was then dried down overnight under nitrogen.  The resulting solid, crude 
mixture was then subjected to an aqueous workup using chloroform, water, and brine.  After 
separating the organic phase, it was dried using sodium sulfate and then filtered, and 
evaporated.  A flash column using a hexane:EtOAc gradient was used, which ranged from 7:1 to 
1:1.  Yield: 84%  1H NMR (400 MHz, Chloroform-d) δ 7.61 – 7.51 (m, 25H), 7.51 – 7.39 (m, 15H), 
7.38 – 7.17 (m, 16H), 4.71 (d, J = 3.9 Hz, 4H), 4.12 (dd, J = 10.1, 4.9 Hz, 4H), 3.98 (td, J = 9.1, 1.8 
Hz, 13H), 3.92 (dd, 1H), 3.78 (t, J = 10.3 Hz, 4H), 3.61 (t, J = 9.5 Hz, 26H), 3.51 (td, J = 4.0 Hz, 2H), 
2.74 (d, J = 2.3 Hz, 4H), 2.24 (d, J = 9.6 Hz, 5H).   
 
 
General method for the synthesis of esters for headgroup 21:     These syntheses were 
performed typically using about 120 mg (0.33 mmol) of headgroup 21, which was dissolved 
within 2mL of anhydrous DCM and stirred at 00C.  Then, about 5eq of pyridine is added, after 
which 1.3 equivalents of the appropriate acid chloride was added.  The reaction mixture was 
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then allowed to warm to room temperature spontaneously within the ice bath used.  After 
about 24hrs of reaction progression, the reaction was discontinued and a flash column was 
performed using a hexane:EtOAc gradient.  If the acid chloride was not available, it was 
synthesized using 1.2-1.4 eq of the corresponding carboxylic acid, which was dissolved within 
1.8 mL of DCM and stirred at room temperature.  To this solution, 1eq of oxalyl chloride and 
one drop of DMF were added.  After the acid chloride is maximally formed, this solution is 
added directly to the headgroup.  Typically, the products isolated include a 2 and 3 monoesters, 
as well as the diester. 
 
 
Synthesis of pentanoyl ester 25:     The acid chloride was synthesized from pentanoic acid, oxalyl 
chloride, and DMF in dichloromethane at temperatures ranging from 00C to room temperature.  
Added headgroup directly to acid chloride solution after about 1.5hrs.  After about 24hrs, the 
reaction was discontinued and a flash column was performed using a hexane:EtOAc gradient 
which gave the pure 2-isomer and dimer with yields of 13% and 31.% respectively.  2-isomer  1H 
NMR (400 MHz, CDCl3) δ 7.57 (d, J = 7.2 Hz, 2H), 7.46 (d, J = 7.7 Hz, 4H), 7.42 (d, J = 7.8 Hz, 2H), 
7.36 – 7.31 (m, 1H), 7.30 – 7.20 (m, 6H), 4.84 (d, J = 3.7 Hz, 1H), 4.72 (dd, J = 9.7, 3.8 Hz, 1H), 
4.22 (td, J = 9.4, 3.4 Hz, 1H), 4.12 (dd, J = 10.1, 4.9 Hz, 1H), 3.96 (td, 1H), 3.80 (t, J = 10.3 Hz, 1H), 
3.69 (t, J = 9.5 Hz, 1H), 3.37 (s, 3H), 2.45 – 2.38 (m, 3H), 1.63 (dt, J = 15.3, 7.5 Hz, 3H), 1.35 (dt, J 
= 14.6, 7.4 Hz, 2H), 0.92 (t, J = 7.4 Hz, 3H).  13C NMR (101 MHz, Chloroform-d) δ 173.8, 143.5 , 
138.5 , 129.3 , 128.6, 128.2, 127.8 , 125.8 , 102.7 , 97.9 , 75.6 , 73.4 , 69.3 , 64.1 , 63.0 , 55.5 , 
34.0 , 27.2 , 22.3 , 13.9 .  Diester: 1H NMR (400 MHz, Chloroform-d) δ 7.53 – 7.15 (m, 11H), 5.67 
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(t, J = 9.7 Hz, 1H), 4.87 – 4.76 (m, 2H), 4.19 – 3.98 (m, 2H), 3.78 (dt, J = 34.2, 10.0 Hz, 2H), 3.37 
(d, J = 0.7 Hz, 3H), 2.53 – 2.24 (m, 4H), 1.80 – 1.51 (m, 6H), 1.50 – 1.19 (m, 4H), 0.99 – 0.82 (m, 
5H), 0.07 (d, J = 0.7 Hz, 1H).  13C NMR (101 MHz, Chloroform-d) δ 173.4 , 172.7 , 143.4 , 139.1 , 
129.3 , 128.57, 128.1 , 127.3 , 125.4 , 102.3 , 97.9 , 73.4 , 71.5 , 69.1 , 64.3 , 63.3 , 55.5 , 34.4 , 
34.0 , 29.9 , 27.5 , 27.1 , 22.4 , 13.9.  
Synthesis of hexanoyl ester 26:     Standard reaction conditions were performed for this 
reaction, which was discontinued after 26.5 hours.  A flash column was performed using a 
hexane:EtOAc gradient, which afforded pure 2-isomer, 3-isomer, and dimer with 29%, 11%, and 
8% yields respectively.  2 isomer 1H NMR (400 MHz, CDCl3) δ 7.55 (t, J = 10.2 Hz, 1H), 7.50 – 7.38 
(m, 2H), 7.36 – 7.31 (m, 1H), 7.30 – 7.19 (m, 2H), 4.84 (d, J = 3.7 Hz, 1H), 4.72 (dd, J = 9.7, 3.8 Hz, 
1H), 4.22 (td, J = 9.5, 3.4 Hz, 1H), 4.12 (dd, J = 10.0, 5.0 Hz, 1H), 3.96 (td, J = 10.1, 4.8 Hz, 1H), 
3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.5 Hz, 1H), 3.38 (s, 1H), 2.45 (d, J = 3.4 Hz, 1H), 2.43 – 2.37 
(m, 1H), 1.70 – 1.59 (m, 1H), 1.37 – 1.23 (m, J = 22.3, 10.8, 5.6 Hz, 2H), 0.89 (t, J = 6.8 Hz, 2H). 
13C NMR (101 MHz, Chloroform-d) δ 173.5 , 138.3 , 132.4 , 130.0 , 129.1 , 128.4, 127.9, 127.5 , 
125.6 , 97.6 , 97.1 , 76.6 , 75.3 , 73.1 , 71.63 , 70.75 , 70.41 , 69.07 , 63.90 , 62.83 , 61.69 , 55.25 , 
34.0 , 31.1, 24.5 , 22.2 , 13.8 .  Dimer 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 7.3 Hz, 2H), 7.47 – 
7.41 (m, 2H), 7.39 (d, J = 7.6 Hz, 1H), 7.35 – 7.28 (m, 1H), 7.25 – 7.17 (m, 1H), 5.67 (t, J = 9.8 Hz, 
1H), 4.84 (d, J = 3.6 Hz, 2H), 4.79 (dd, J = 9.8, 3.7 Hz, 1H), 4.14 (dd, J = 10.1, 4.9 Hz, 1H), 4.04 (td, 
J = 10.1, 5.0 Hz, 1H), 3.83 (t, J = 10.3 Hz, 1H), 3.74 (t, J = 9.7 Hz, 1H), 3.37 (s, 3H), 2.48 – 2.38 (m, 
1H), 2.31 (td, J = 7.5, 3.7 Hz, 1H), 1.80 – 1.68 (m, 2H), 1.60 (dd, J = 14.5, 7.4 Hz, 2H), 1.36 (d, J = 
3.5 Hz, 2H), 1.33 – 1.26 (m, 3H), 1.25 (s, 1H), 0.88 (td, J = 6.7, 3.2 Hz, 3H).  13C NMR (101 MHz, 
Chloroform-d) δ 173.4 , 172.9 , 143.3 , 139.3 , 135.4 , 129.3 , 128.3 , 127.3 , 125.4 , 97.9 , 77.5 , 
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76.9 , 73.4 , 71.5 , 69.1 , 64.2 , 63.2 , 55.4 , 36.0 , 34.6 , 34.2 , 31.5 , 31.3 , 29.9 , 25.1 , 24.7 , 22.5 
, 14.1 , 1.2 . 
 
 
Synthesis of heptanoyl ester 27:     Standard reaction conditions were applied to this reaction, 
which was discontinued after 24hrs.  1H NMR indicated that only the two isomer and dimer 
were formed. Performed workup with 5% sodium bicarbonate, and then ran a flash column 
using a hexane:EtOAc gradient which afforded the pure 2 isomer and diester giving yields of 
42% and 13% respectively.  2 isomer 1H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 7.3 Hz, 1H), 7.44 
(dd, J = 15.7, 7.3 Hz, 2H), 7.34 (t, J = 7.3 Hz, 1H), 7.31 – 7.21 (m, 2H), 4.84 (d, J = 3.7 Hz, 1H), 4.72 
(dd, J = 9.7, 3.7 Hz, 1H), 4.22 (td, J = 9.5, 3.3 Hz, 1H), 4.12 (dd, J = 10.1, 4.9 Hz, 1H), 3.96 (td, J = 
10.1, 4.9 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.5 Hz, 1H), 3.37 (s, 1H), 2.46 (d, J = 3.4 Hz, 
1H), 2.40 (t, J = 7.5 Hz, 1H), 1.69 – 1.59 (m, 1H), 1.37 – 1.24 (m, 3H), 0.88 (t, J = 6.6 Hz, 1H).  13C 
NMR (101 MHz, Chloroform-d) δ 173.8 , 143.5 , 138.5 , 129.3 , 128.4 , 127.8 , 125.8 , 102.7 , 
97.9 , 75.6 , 73.4 , 69.3 , 64.1 , 63.1 , 55.5 , 34.3 , 31.6 , 28.8 , 25.1 , 22.7 , 14.2 .  Dimer  1H NMR 
(400 MHz, CDCl3) δ 7.48 (t, J = 7.0 Hz, 2H), 7.44 (dd, J = 9.0, 4.5 Hz, 4H), 7.40 (d, J = 7.1 Hz, 2H), 
7.35 – 7.29 (m, 4H), 7.28 – 7.22 (m, 2H), 7.22 – 7.17 (m, 2H), 5.67 (t, J = 9.7 Hz, 1H), 4.84 (d, J = 
3.6 Hz, 1H), 4.82 – 4.77 (m, 1H), 4.15 (dd, J = 10.0, 4.9 Hz, 1H), 4.04 (td, J = 10.0, 4.9 Hz, 1H), 
3.83 (t, J = 10.2 Hz, 1H), 3.74 (t, J = 9.7 Hz, 1H), 3.38 (s, 3H), 2.50 – 2.38 (m, 2H), 2.37 – 2.27 (m, 
2H), 1.79 – 1.66 (m, 2H), 1.64 – 1.54 (m, 3H), 1.45 – 1.35 (m, 10H), 1.35 – 1.23 (m, 6H), 0.88 (q, J 
= 6.1 Hz, 3H).  13C NMR (101 MHz, Chloroform-d) δ 173.4 , 172.7 , 143.3 , 139.1 , 129.3 , 128.3 , 
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127.3 , 125.4 , 97.9 , 73.4 , 71.5 , 69.1 , 64.3 , 63.2 , 55.4 , 34.6 , 34.3 , 31.6 , 29.9 , 29.0 , 25.4 , 
25.0 , 22.6 , 14.2 , 1.2 . 
 
 
Synthesis of octanoyl ester 28:  Standard reaction conditions were applied, under which the 2 
isomer and dimer formed primarily.  The reaction was discontinued after about 24hrs, and a 
flash column was performed using a hexane:EtOAc gradient which afforded pure 2-ismomer 
and dimer with yields of 43% and 17% respectively.  2 isomer 1H NMR (400 MHz, CDCl3) δ 7.57 
(d, J = 7.3 Hz, 2H), 7.44 (dd, J = 15.6, 7.6 Hz, 4H), 7.34 (t, J = 7.3 Hz, 1H), 7.30 – 7.18 (m, 6H), 4.84 
(d, J = 3.7 Hz, 1H), 4.72 (dd, J = 9.7, 3.8 Hz, 1H), 4.22 (t, J = 9.5 Hz, 1H), 4.12 (dd, J = 10.1, 4.9 Hz, 
1H), 3.96 (td, J = 10.2, 4.8 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.5 Hz, 1H), 3.37 (s, 3H), 
2.40 (t, J = 7.5 Hz, 2H), 1.63 (dd, J = 14.4, 7.0 Hz, 3H), 1.36 – 1.23 (m, 9H), 0.88 (t, J = 6.8 Hz, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 173.7 , 143.5 , 138.5 , 129.3 , 128.4 , 127.8 , 125.8 , 97.9 , 
75.2 , 73.6 , 69.3 , 64.1 , 63.0 , 55.5 , 34.3 , 31.8 , 29.1 , 25.0 , 22.3 , 14.30 .  Dimer  1H NMR (400 
MHz, CDCl3) δ 7.47 (dd, J = 13.2, 4.4 Hz, 4H), 7.41 (dd, J = 13.9, 6.5 Hz, 13H), 7.31 (t, J = 7.0 Hz, 
2H), 7.27 – 7.22 (m, 4H), 7.21 – 7.17 (m, 1H), 5.67 (t, J = 9.8 Hz, 1H), 4.84 (d, J = 3.7 Hz, 1H), 4.80 
(dd, J = 9.8, 3.7 Hz, 1H), 4.14 (dd, J = 10.1, 4.9 Hz, 1H), 4.04 (td, J = 10.1, 4.9 Hz, 1H), 3.83 (t, J = 
10.3 Hz, 1H), 3.74 (t, J = 9.7 Hz, 1H), 3.37 (s, 3H), 2.49 – 2.37 (m, 3H), 2.37 – 2.27 (m, 2H), 1.79 – 
1.68 (m, 2H), 1.64 – 1.54 (m, 3H), 1.43 – 1.22 (m, 16H), 0.87 (dt, J = 9.2, 6.8 Hz, 7H).  13C NMR 
(101 MHz, Chloroform-d) δ 173.4 , 172.7 , 143.3 , 139.1 , 129.3 , 128.3 , 127.3 , 125.4 , 102.3 , 
97.9 , 73.4 , 71.5 , 69.1 , 64.3 , 63.2 , 55.4 , 34.7 , 34.3 , 31.8 , 29.2 , 25.4 , 25.1 , 22.8 , 14.2 , 1.2 . 
 
66 
 
Synthesis of 4-chlorobutyl ester 29:     Standard reaction conditions were applied, under which 
the 2-isomer and dimer were formed primarily. After about 24hrs, discontinued reaction and 
worked up with 5% a sodium bicarbonate aqueous solution, and then performed a flash column 
using a hexane:EtOAc gradient.  This afforded pure 2-isomer and dimer giving 40% and 20% 
yields respectively.  2 isomer 1H NMR (400 MHz, CDCl3) δ 7.60 – 7.55 (m, 2H), 7.45 (q, 2H), 7.34 
(t, J = 7.3 Hz, 1H), 7.31 – 7.20 (m, 2H), 4.84 (d, J = 3.7 Hz, 1H), 4.74 (dd, J = 9.7, 3.8 Hz, 1H), 4.23 
(td, J = 9.5, 3.4 Hz, 1H), 4.13 (dd, J = 10.1, 4.9 Hz, 1H), 3.96 (td, J = 10.1, 4.9 Hz, 1H), 3.80 (t, J = 
10.3 Hz, 1H), 3.69 (t, J = 9.6 Hz, 1H), 3.60 (t, 1H), 3.38 (s, 3H), 2.61 (t, J = 6.9 Hz, 2H), 2.52 (dd, J = 
3.4, 0.9 Hz, 1H), 2.16 – 2.07 (m, 2H).  13C NMR (101 MHz, Chloroform-d) δ 172.6 , 143.4 , 138.51 
, 129.1 , 128.4 , 127.8 , 125.8 , 102.7 , 97.8 , 76.5 , 75.6 , 73.6 , 69.3 , 64.1 , 63.1 , 55.5 , 44.0 , 
31.3 , 27.8 .  Dimer  1H NMR (400 MHz, CDCl3) δ 7.48 (t, J = 7.2 Hz, 3H), 7.46 – 7.40 (m, 4H), 7.33 
(t, J = 7.2 Hz, 2H), 7.28 – 7.17 (m, 2H), 5.67 (t, J = 9.8 Hz, 1H), 4.86 (d, J = 3.7 Hz, 1H), 4.82 (dd, J 
= 9.8, 3.7 Hz, 1H), 4.15 (dd, J = 10.1, 4.9 Hz, 1H), 4.04 (td, J = 10.1, 4.9 Hz, 1H), 3.84 (t, J = 10.3 
Hz, 1H), 3.76 (t, J = 9.7 Hz, 1H), 3.66 (t, J = 6.3 Hz, 2H), 3.59 (t, J = 6.3 Hz, 2H), 3.39 (s, 1H), 2.74 – 
2.59 (s, 3H), 2.54 (t, J = 7.2 Hz, 3H), 2.18 (dtd, J = 13.6, 6.9, 2.3 Hz, 2H), 2.07 (tt, J = 13.7, 6.7 Hz, 
2H).  13C NMR (101 MHz, Chloroform-d) δ 172.2 , 171.7 , 143.2 , 138.9 , 129.4 , 128.5 , 128.2 , 
127.3 , 125.4 , 102.4 , 97.7 , 76.9 , 73.3 , 71.8 , 69.6 , 64.2 , 63.2 , 55.5 , 44.0 , 31.2 , 27.8 , 27.6 . 
 
 
Synthesis of 6-bromohexanoyl ester 30:     Standard reaction conditions were applied, and after 
a duration of 48hrs, the reaction was discontinued and worked-up using 5%  sodium 
bicarbonate in aqueous solution.  The 2-isomer and dimer were isolated after performing 
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column chromatography, affording yields of 38% and 11% respectively.  2-Isomer 1H NMR (400 
MHz, CDCl3) δ 7.57 (d, J = 7.3 Hz, 2H), 7.45 (q, 2H), 7.34 (t, J = 7.3 Hz, 2H), 7.30 – 7.21 (m, 2H), 
4.84 (d, J = 3.7 Hz, 1H), 4.73 (dd, J = 9.7, 3.8 Hz, 1H), 4.22 (td, J = 9.5, 3.4 Hz, 1H), 4.13 (dd, J = 
10.1, 4.9 Hz, 1H), 3.96 (td, J = 10.1, 4.9 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.5 Hz, 1H), 
3.53 (t, J = 6.6 Hz, 1H), 3.40 (dd, J = 10.8, 4.0 Hz, 1H), 3.38 (s, 3H), 2.48 (d, J = 3.5 Hz, 1H), 2.43 (t, 
J = 7.3 Hz, 1H), 1.92 – 1.84 (m, 2H), 1.84 – 1.75 (m, 1H), 1.73 – 1.63 (m, 2H), 1.50 (ddd, J = 18.5, 
8.9, 6.0 Hz, 2H).  13C NMR (101 MHz, Chloroform-d) δ 167.4 , 143.5 , 138.5 , 134.0 , 130.9 , 129.4 
, 128.9, 128.2, 128.1 , 127.9 , 126.5 , 125.96 , 124.7 , 98.0 , 75.7 , 74.2 , 69.5 , 64.2 , 63.1 , 55.71 
.  Diester: 1H NMR (400 MHz, Chloroform-d) δ 7.56 – 7.39 (m, 3H), 7.39 – 7.16 (m, 5H), 4.85 (d, J 
= 3.8 Hz, 1H), 4.80 (dt, J = 10.0, 2.4 Hz, 0H), 4.21 – 3.98 (m, 1H), 3.78 (dt, J = 32.9, 10.0 Hz, 1H), 
3.57 – 3.27 (m, 3H), 2.55 – 2.26 (m, 2H), 1.88 (h, J = 7.0 Hz, 6H), 1.67 – 1.57 (m, 1H), 1.54 – 1.41 
(m, 1H).  13C NMR (101 MHz, Chloroform-d) δ 172.7 , 172.1 , 143.0 , 138.6 , 132.4 , 130.0 , 129.1 
, 128.2 , 128.0 , 127.1 , 125.2 , 102.2 , 97.6 , 76.6 , 73.1 , 71.4 , 69.1 , 64.0 , 63.0 , 55.2 , 44.7 , 
34.1 , 33.7 , 33.3 , 32.2 , 29.6 , 27.5 , 26.2 , 24.3 , 24.0 , 22.6  . 
 
 
Synthesis of 4-pentynoyl ester 31:     The acid chloride was not available, therefore it was 
prepared using the aforementioned procedure.  The yields obtained for the 2-isomer, 3-isomer, 
and dimer were: 30%, 9%, and 5% respectively.  2 isomer 1H NMR (400 MHz, CDCl3) δ 7.58 (d, 
2H), 7.45 (q, 2H), 7.34 (t, J = 7.3 Hz, 1H), 7.30 – 7.20 (m, 2H), 4.85 (d, J = 3.7 Hz, 1H), 4.74 (dd, J = 
9.7, 3.8 Hz, 1H), 4.24 (td, J = 9.5, 2.5 Hz, 1H), 4.13 (dd, J = 10.1, 4.9 Hz, 1H), 3.97 (td, J = 10.2, 4.9 
Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.70 (t, J = 9.5 Hz, 1H), 3.38 (s, 3H), 2.69 – 2.62 (m, 2H), 2.60 – 
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2.50 (m, 3H), 2.01 (t, J = 2.6 Hz, 1H). 3 isomer 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 7.8 Hz, 
1H), 7.43 (dd, J = 13.0, 7.3 Hz, 2H), 7.32 (t, J = 7.3 Hz, 1H), 7.28 – 7.17 (m, 2H), 5.41 (t, J = 9.6 Hz, 
1H), 4.72 (d, J = 3.8 Hz, 1H), 4.14 (dd, J = 10.1, 4.9 Hz, 1H), 3.98 (td, J = 10.1, 4.8 Hz, 1H), 3.81 (t, 
J = 10.3 Hz, 1H), 3.67 (t, J = 9.7 Hz, 1H), 3.55 (td, 1H), 3.43 (s, 1H), 2.77 (t, J = 7.2 Hz, 1H), 2.64 
(ddd, J = 14.9, 7.3, 2.5 Hz, 1H), 2.20 (d, J = 11.4 Hz, 1H), 1.95 (t, J = 2.6 Hz, 1H).  13C NMR (101 
MHz, Chloroform-d) δ 169.1 , 141.0 , 136.0 , 126.9 , 125.9 , 125.3 , 123.4 , 100.2 , 95.3 , 80.1 , 
75.0 , 74.7 , 74.4 , 73.0 , 71.5 , 66.9 , 66.7 , 61.6 , 60.6 , 53.0 , 30.9 , 12.1 .  Dimer 1H NMR (400 
MHz, CDCl3) δ 7.53 – 7.36 (m, 2H), 7.31 (dd, J = 14.2, 6.9 Hz, 1H), 7.26 – 7.17 (m, 2H), 5.68 (t, J = 
9.5 Hz, 1H), 4.85 (t, J = 4.4 Hz, 1H), 4.82 (d, J = 3.7 Hz, 1H), 4.15 (dd, J = 10.1, 5.0 Hz, 1H), 4.04 
(td, J = 10.1, 4.9 Hz, 1H), 3.84 (t, J = 10.3 Hz, 1H), 3.75 (t, J = 9.7 Hz, 1H), 3.38 (s, 3H), 2.73 – 2.67 
(m, 2H), 2.64 – 2.56 (m, 2H), 2.52 – 2.45 (m, 1H), 1.98 (t, J = 2.6 Hz, 1H), 1.95 (t, J = 2.6 Hz, 1H).  
 
 
Synthesis of 5-hexynoyl ester 32:  C2 Yield: 19%; Diester Yield: 14%  1H NMR (400 MHz, 
Chloroform-d) δ 7.56 (d, 4H), 7.50 – 7.36 (m, 16H), 7.31 – 7.15 (m, 7H), 4.90 – 4.80 (m, 5H), 4.73 
(dd, J = 9.7, 3.7, 0.9 Hz, 2H), 4.23 (t, 5H), 4.13 (q, 2H), 3.96 (td, J = 10.1, 4.9 Hz, 4H), 3.80 (t, J = 
10.3 Hz, 2H), 3.69 (t, 2H), 3.39 (s, 7H), 2.63 – 2.36 (m, 8H), 2.27 (tddt, J = 12.5, 9.3, 6.1, 2.8 Hz, 
7H), 2.02 – 1.72 (m, 10H).  13C NMR (101 MHz, Chloroform-d) δ 172.6 , 172.0 , 143.3 , 139.0 , 
129.3 , 128.3 , 127.3 , 125.4 , 102.3 , 97.8 , 83.3 , 77.5 , 73.2 , 71.7 , 69.5 , 64.2 , 63.2 , 55.5 , 32.8 
, 23.9 , 23.6 , 17.9 (d, J = 6.2 Hz).  Diester:  1H NMR (400 MHz, Chloroform-d) δ 7.44 (s, 6H), 7.36 
– 7.15 (m, 7H), 5.67 (t, J = 9.8 Hz, 1H), 4.84 (d, 2H), 4.80 (dd, 1H), 4.15 (q, J = 10.1, 4.9 Hz, 1H), 
4.04 (td, J = 10.1, 5.0 Hz, 1H), 3.83 (t, J = 10.3 Hz, 2H), 3.73 (t, J = 9.7 Hz, 1H), 3.38 (d, J = 0.7 Hz, 
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3H), 2.71 – 2.44 (m, 4H), 2.29 (dtd, J = 34.5, 7.0, 2.7 Hz, 4H), 2.02 – 1.77 (m, 5H).  13C NMR (101 
MHz, Chloroform-d) δ 172.3 , 171.8 , 143.0 , 138.7 , 129.1 , 128.0 , 127.1 , 125.2 , 102.1 , 97.5 , 
82.9 , 76.6 , 73.8 , 71.4 , 69.8 , 64.0 , 63.0 , 55.2 , 32.6 , 29.6 , 23.6 , 23.4 , 17.6. 
 
 
Synthesis of 6-heptynoyl ester 33:  C2 Yield: 11%; Diester Yield: 10%  1H NMR (400 MHz, 
Chloroform-d) δ 7.57 (dd, 2H), 7.50 – 7.39 (m, 4H), 7.38 – 7.18 (m, 5H), 4.84 (d, J = 3.8 Hz, 1H), 
4.72 (dd, 1H), 4.22 (td, J = 9.4, 3.4 Hz, 1H), 4.17 – 4.08 (m, 1H), 3.96 (td, J = 10.2, 4.8 Hz, 1H), 
3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.4 Hz, 1H), 3.38 (s, 3H), 2.49 – 2.39 (m, 3H), 2.22 (td, J = 7.1, 
2.7 Hz, 2H), 1.99 – 1.92 (m, 1H), 1.78 (p, J = 7.3 Hz, 2H), 1.64 – 1.56 (m, 2H).  13C NMR (101 MHz, 
Chloroform-d) δ 173.3 , 143.5 , 138.2 , 129.4 , 128.4 , 127.8 , 125.8 , 97.8 , 75.8 , 75.6 , 73.5 , 
69.3 , 68.8 , 64.1 , 63.0 , 55.5 , 33.7 , 27.8 , 24.1 , 18.3 .  Diester:  1H NMR (400 MHz, Chloroform-
d) δ 7.52 – 7.37 (m, 6H), 7.36 – 7.15 (m, 4H), 5.66 (t, J = 9.8, 1.0 Hz, 1H), 4.85 (d, J = 3.7 Hz, 2H), 
4.80 (dd, J = 9.8, 3.7, 1.0 Hz, 1H), 4.25 – 4.10 (m, 1H), 4.03 (td, J = 10.0, 4.9 Hz, 1H), 3.84 (t, J = 
10.3, 9.2 Hz, 2H), 3.74 (t, 1H), 3.38 (s, 3H), 2.56 – 2.41 (m, 9H), 2.39 – 2.32 (m, 1H), 2.21 (ddd, J 
= 10.8, 6.9, 2.6 Hz, 4H), 1.99 – 1.89 (m, 12H), 1.76 – 1.63 (m, 1H), 1.65 – 1.50 (m, 5H). 13C NMR 
(101 MHz, Chloroform-d) δ 172.9 , 172.3 , 143.3 , 139.0 , 129.3 , 128.3 , 127.3 , 125.4 , 102.3 , 
97.8 , 83.9 , 76.9 , 73.2 , 71.6 , 69.3 , 69.0 , 64.2 , 63.2 , 55.5 , 34.1 , 33.7 , 27.9 , 24.4 , 24.1 , 18.3 
. 
 
    
70 
 
Synthesis of benzoyl ester 34:  C2 Yield:  55%; Diester: 10%  C2: 1H NMR (400 MHz, Chloroform-
d) δ 8.09 (d, J = 7.1, 1.1 Hz, 2H), 7.65 – 7.54 (m, 3H), 7.52 – 7.40 (m, 6H), 7.41 – 7.31 (m, 4H), 
7.33 – 7.17 (m, 3H), 4.96 (d, 2H), 4.39 (t, 1H), 4.16 (dd, J = 10.0, 4.9 Hz, 1H), 4.03 (td, J = 10.1, 
4.9 Hz, 1H), 3.84 (t, J = 10.3 Hz, 2H), 3.77 (t, J = 9.5 Hz, 1H), 3.38 (s, 3H).  13C NMR (101 MHz, 
Chloroform-d) δ 166.5 , 143.6 , 138.6 , 133.6 , 130.2 , 129.7 , 129.4 , 128.5 , 127.9 , 125.9 , 98.09 
, 77.6 , 75.7 , 74.2 , 69.4 , 64.2 , 63.1 , 55.6 .  Diester:  1H NMR (400 MHz, Chloroform-d) δ 8.12 
(d, J = 7.1, 1.2 Hz, 2H), 8.00 (d, J = 8.4, 1.2 Hz, 2H), 7.65 – 7.45 (m, 16H), 7.43 – 7.27 (m, 6H), 
7.28 – 7.14 (m, 3H), 6.12 (t, J = 9.6, 1.0 Hz, 1H), 5.11 (d, J = 12.6, 3.4, 1.0 Hz, 2H), 5.08 (dd, J = 
0.9 Hz, 0H), 4.28 – 4.13 (m, 2H), 3.96 (t, 2H), 3.41 (s, 3H).  13C NMR (101 MHz, Chloroform-d) δ 
166.2 , 165.7 , 143.3 , 139.1 , 133.5 , 130.0 , 129.3 , 128.6 , 128.2 , 127.4 , 125.5 , 102.5 , 98.0 , 
73.8 , 72.7 , 69.9 , 64.6 , 63.3 , 55.6 . 
 
Synthesis of naphthoyl ester 35:     Discontinued reaction after about 22hrs, at which time the 
reaction conversion was about 95%.  After performing a flash column using a hexane:EtOAc 
gradient, the yield obtained was 64%.  1H NMR (400 MHz, CDCl3) δ 8.90 (d, J = 8.6 Hz, 1H), 8.25 
(d, J = 7.2 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.61 (dd, J = 8.1, 2.0 Hz, 4H), 
7.50 (ddd, J = 23.7, 15.7, 7.9 Hz, 7H), 7.39 – 7.32 (m, 2H), 7.31 – 7.22 (m, 4H), 5.07 (dt, J = 9.3, 
3.8 Hz, 2H), 4.45 (td, J = 9.3, 3.3 Hz, 1H), 4.18 (dd, J = 10.0, 4.9 Hz, 1H), 4.12 – 4.00 (m, 1H), 3.86 
(t, J = 16.4, 5.7 Hz, 1H), 3.80 (t, J = 9.5 Hz, 1H), 3.42 (s, 3H), 2.62 (d, J = 3.3 Hz, 1H).  13C NMR 
(101 MHz, Chloroform-d) δ 167.4 , 143.5 , 138.5 , 134.0 , 130.9 , 129.4 , 128.5 , 128.1 , 127.0 , 
126.5 , 125.9 , 124.7 , 102.8 , 98.0 , 75.7 , 74.2 , 69.5 , 64.2 , 63.1 , 55.7 . 
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General method for the synthesis of the carbamates from headgroup 21: To a scintillation vial, 
0.5mmol of compound 21   was dissolved in 2 mL of DCM or THF and stirred at rt-30 C.  Then, 
about 0.6mmol of the corresponding isocynate and a drop of anhydrous triethyl amine were 
added to the solution. The mixture was left stirring for 12-18 hs, after which time the mixture 
was concentrated to dryness under nitrogen or rotavap (for larger scale).  The crude residue 
was purified by flash chromatography using a hexane/EtOAc gradient(9:1 to 3:1). The purified 
compound was subjected to gelation screening.   
 
Synthesis of pentyl carbamate 36:    The crude product was diluted with hexane/EtOAc and 
filtered and then washed with hexane, and the product obtained is pure.  Isolated pure product 
using this method, giving a yield of 65% of pure material.  1H NMR (400 MHz, CDCl3) δ 7.49 (dd, 
J = 6.6, 3.0 Hz, 1H), 7.38 (ddd, J = 7.0, 4.7, 1.4 Hz, 1H), 5.55 (s, 1H), 4.95 – 4.69 (m, 1H), 4.33 (dd, 
J = 10.4, 5.0 Hz, 1H), 4.16 (dd, J = 11.1, 5.8 Hz, 1H), 3.86 (t, J = 9.1 Hz, 1H), 3.71 (t, J = 10.3 Hz, 
1H), 3.54 (t, J = 9.3 Hz, 1H), 3.45 – 3.35 (m, 1H), 3.30 (t, J = 10.8 Hz, 1H), 3.15 (dt, J = 12.5, 6.3 
Hz, 1H), 1.49 (dt, J = 14.3, 7.3 Hz, 2H), 1.41 – 1.23 (m, 8H), 0.89 (t, J = 7.0 Hz, 2H).  13C NMR (101 
MHz, CDCl3) δ 156.0, 137.6, 128.8, 126.5, 102.2, 81.2, 73.3, 72.7, 71.4, 68.9, 41.6, 29.6, 29.2, 
22.5, 14.1.   
 
5-hexynyl carbamate 37:    The isocyanate was formed via curtius rearrangement of 6-heptynoic 
acid using DPPA and TEA in THF at 600C.  The resulting product was then added directly to the 
sugar headgroup.  Column purification employing a hexane:EtOAc gradient afforded a 15% 
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yield. 1H NMR (400 MHz, Chloroform-d) δ 7.61 – 7.53 (m, 2H), 7.51 – 7.42 (m, 9H), 7.38 – 7.26 
(m, 3H), 7.27 – 7.12 (m, 1H), 4.96 (t, J = 5.9 Hz, 1H), 4.85 (d, J = 3.7 Hz, 1H), 4.64 (dd, J = 9.7, 3.8, 
1.0 Hz, 1H), 4.22 – 4.02 (m, 3H), 3.94 (td, J = 10.1, 4.8 Hz, 1H), 3.80 (t, 1H), 3.69 (t, J = 9.5 Hz, 
1H), 3.39 (s, 3H), 3.22 (q, J = 6.7 Hz, 3H), 2.70 (d, J = 3.6 Hz, 1H), 2.21 (td, J = 6.9, 3.1 Hz, 3H), 
1.99 – 1.91 (m, 1H), 1.69 – 1.51 (m, 10H), 1.26 (t, J = 7.1, 1.0 Hz, 2H).  13C NMR (101 MHz, 
Chloroform-d) δ 156.1 , 143.5 , 138.5 , 135.4 , 129.3 , 128.6, 128.1, 127.8 , 125.8 , 102.7 , 98.4 , 
84.1 , 77.5 , 75.7 , 74.0 , 69.6 , 68.9 , 64.1 , 63.1 , 55.4 , 40.8 , 29.9 , 29.0 , 25.6 , 18.2 , 1.2.  
 
 
Synthesis of cyclohexyl carbamate  38:     The crude was product was purified on a flash column 
using hexane:DCM:acetone, the purified product has trace amount of urea byproduct.  Yield:  
13%;  1H NMR (400 MHz, Chloroform-d) δ 7.62 – 7.54 (m, 2H), 7.52 – 7.38 (m, 4H), 7.38 – 7.17 
(m, 4H), 4.85 (d, 2H), 4.62 (dd, J = 9.7, 3.8 Hz, 1H), 4.22 – 4.13 (m, 2H), 4.15 – 4.10 (m, 1H), 3.95 
(td, J = 10.1, 4.8 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.69 (t, J = 9.5 Hz, 1H), 3.53 – 3.41 (m, 1H), 
3.40 (s, 3H), 2.65 (d, J = 3.5 Hz, 1H), 1.75 – 1.65 (m, 7H), 1.63 – 1.52 (m, 2H), 1.42 – 1.27 (m, 7H), 
1.20 – 1.05 (m, 4H).    
 
Benzyl carbamate 39:  Yield:  13%; 1H NMR (400 MHz, Chloroform-d) δ 7.62 – 7.54 (m, 2H), 7.51 
– 7.39 (m, 4H), 7.38 – 7.18 (m, 11H), 5.24 (t, J = 6.0 Hz, 1H), 4.88 (d, J = 3.8 Hz, 1H), 4.69 (dd, J = 
9.7, 3.7 Hz, 1H), 4.45 – 4.30 (m, 2H), 4.19 (td, J = 9.4, 3.3 Hz, 2H), 4.13 (dd, J = 10.1, 4.8 Hz, 1H), 
3.95 (td, J = 10.1, 4.9 Hz, 1H), 3.80 (t, J = 10.3 Hz, 1H), 3.70 (t, J = 9.5 Hz, 1H), 3.40 (s, 3H), 2.62 
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(d, J = 3.5 Hz, 1H).  13C NMR (101 MHz, Chloroform-d) δ 156.1 , 143.5 , 138.5 , 138.1 , 129.3 , 
128.9 , 128.6, 128.1, 127.81, 125.8 , 98.4 , 75.6 , 74.3 , 69.6 , 64.1 , 63.1 , 55.5 , 45.4 , 29.9 . 
 
Synthesis of N-acetyl-4,6-O-diphenyl-methyl-α-glucosamine 42:  To a 500 mL round bottomed flask, 3.52 
g (14.9 mmol) of α-methyl-D-glucosamine was added and dissolved within 40 mL of DMF and stirred at 
room temperature.  To this solution, 6.11 g (2.25 equivalents) of benzophenone dimethyl acetal 23 was 
added and the solution was brought to 1000C.  To this hot solution, 20 mol% of p-toluene sulfonic acid 
was added.  Once the reaction peaked, stirring was discontinued and the flask was adapted to a rotary 
evaporator.  After removing the methanol byproduct, the reaction proceeded further.  At this point, the 
solvent was removed via a nitrogen stream overnight, and then a workup was performed using 
DCM/water.  After isolation of the organic phase, it was dried with sodium sulfate, filtered, and 
evaporated.  The crude mixture was subsequently purified via flash chromatography using a 
hexane:EtOAc gradient ranging from 7:1 to pure EtOAc.  
1H NMR (400 MHz, Chloroform-d) δ 7.59 
(dd, J = 8.2, 1.1 Hz, 6H), 7.49 (dd, J = 8.2, 1.2 Hz, 6H), 7.42 (t, 12H), 7.34 – 7.30 (m, 2H), 7.29 – 
7.16 (m, 13H), 5.86 (d, J = 8.8 Hz, 3H), 5.29 (d, J = 1.1 Hz, 1H), 4.60 (d, J = 3.8 Hz, 3H), 4.11 
(dddd, J = 9.7, 8.6, 4.1, 1.0 Hz, 6H), 3.99 – 3.84 (m, 13H), 3.80 (t, 3H), 3.70 (t, 3H), 3.37 (s, 8H), 
3.07 (d, J = 3.9, 1.0 Hz, 3H), 1.63 (s, 2H). 
 
Pentyl amide 44:  Yield:  88%;  1H NMR (400 MHz, Chloroform-d) δ 7.85 – 7.77 (m, 2H), 7.64 – 
7.55 (m, 5H), 7.54 – 7.38 (m, 10H), 7.37 – 7.16 (m, 7H), 5.82 (d, J = 8.8 Hz, 2H), 4.60 (d, J = 3.8 
Hz, 2H), 4.12 (td, J = 9.7, 4.3 Hz, 4H), 3.98 – 3.83 (m, 8H), 3.78 (t, 2H), 3.69 (t, J = 9.3 Hz, 1H), 
3.37 (s, 8H), 3.09 (d, J = 3.7 Hz, 2H), 2.25 (td, J = 7.7, 1.3 Hz, 4H), 1.73 – 1.55 (m, 9H), 1.45 – 1.28 
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(m, 4H), 1.25 (s, 1H), 0.92 (t, J = 7.3 Hz, 7H).  13C NMR (101 MHz, Chloroform-d) δ 174.9 , 143.7 , 
138.8 , 135.4 , 132.6 , 130.3 , 129.3 , 128.62,  128.1, 127.8 , 125.7 , 102.5 , 99.0 , 76.9 , 76.2 , 
71.5 , 64.1 , 63.4 , 55.3 , 54.1 , 36.6 , 27.9 , 22.4 , 14.0 . 
 
Hexyl amide 45:  Yield: 73%;  1H NMR (400 MHz, Chloroform-d) δ 7.60 (d, 2H), 7.58 (s, 5H), 7.53 
– 7.38 (m, 9H), 7.37 – 7.28 (m, 10H), 7.30 – 7.07 (m, 7H), 5.82 (d, J = 8.7 Hz, 2H), 5.30 (d, J = 0.7 
Hz, 1H), 4.60 (d, J = 3.8 Hz, 2H), 4.12 (td, J = 9.7, 4.2 Hz, 5H), 4.00 – 3.86 (m, 8H), 3.80 (t, J = 10.2 
Hz, 2H), 3.70 (t, J = 9.3 Hz, 2H), 3.37 (d, J = 0.7 Hz, 6H), 2.24 (t, 5H), 1.73 – 1.60 (m, 6H), 1.40 – 
1.23 (m, 11H), 0.90 (t, J = 6.8, 5.8, 2.8 Hz, 7H).  13C NMR (101 MHz, Chloroform-d) δ 174.9 , 
143.7 , 138.8 , 129.3 , 128.5, 128.1, 127.8 , 125.7 , 102.5 , 99.0 , 77.5 , 76.2 , 71.5 , 64.1 , 63.4 , 
55.3 , 54.1 , 36.8 , 31.5 , 25.5 , 22.5 , 14.1 . 
 
Heptyl amide 46:  Yield: 40%;  1H NMR (400 MHz, Chloroform-d) δ 7.63 – 7.55 (m, 2H), 7.53 – 
7.38 (m, 4H), 7.37 – 7.26 (m, 3H), 7.29 – 7.05 (m, 1H), 5.82 (d, J = 8.8 Hz, 1H), 5.30 (s, 1H), 4.60 
(d, J = 3.8 Hz, 1H), 4.12 (td, J = 9.3, 4.1 Hz, 2H), 3.91 (dtd, J = 14.8, 9.7, 4.1 Hz, 4H), 3.81 (t, J = 
10.2 Hz, 1H), 3.71 (t, J = 9.3 Hz, 1H), 3.37 (s, 3H), 3.08 (d, J = 4.0 Hz, 1H), 2.24 (t, J = 7.5 Hz, 2H), 
1.68 – 1.58 (m, 3H), 1.42 – 1.23 (m, 8H), 0.92 – 0.84 (m, 3H).  13C NMR (101 MHz, Chloroform-d) 
δ 174.40 (d, J = 2.4 Hz), 143.7 , 138.7 , 132.6 , 130.3 , 129.3 , 128.68, 128.1, 127.81 , 125.7 , 99.0 
, 76.2 , 71.4 , 64.1 , 63.4 , 55.4 , 54.1 , 45.1 , 36.5, 33.9, 32.5 , 29.9 , 27.8 , 26.5 , 24.9 . 
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Octanoyl amide 47:  Yield: 37%;    1H NMR (400 MHz, Chloroform-d) δ 7.63 – 7.55 (m, 2H), 7.55 
– 7.38 (m, 4H), 7.37 – 7.30 (m, 6H), 7.28 – 7.11 (m, 2H), 5.82 (d, J = 8.7 Hz, 1H), 4.60 (d, J = 3.8 
Hz, 1H), 4.19 – 4.06 (m, 2H), 3.98 – 3.87 (m, 5H), 3.78 (t, 1H), 3.69 (t, J = 9.3 Hz, 1H), 3.37 (s, 3H), 
3.11 (s, 1H), 2.24 (t, J = 7.5 Hz, 2H), 1.68 – 1.58 (m, 4H), 1.36 – 1.21 (m, 10H), 0.92 – 0.81 (m, 
3H).  13C NMR (101 MHz, Chloroform-d) δ 174.9 , 143.7 , 138.8 , 129.3 , 128.56, 128.1, 127.8 , 
125.7 , 102.5 , 99.0 , 76.2 , 71.6 , 64.1 , 63.4 , 55.3 , 54.1 , 36.8 , 31.8 , 29.9 , 29.2 , 25.8 , 22.8 , 
14.2. 
 
Benzoyl amide 48:  Yield: 85%;   1H NMR (400 MHz, Chloroform-d) δ 7.84 – 7.74 (m, 2H), 7.73 – 
7.58 (m, 14H), 7.54 – 7.45 (m, 5H), 7.45 – 7.34 (m, 2H), 7.27 – 7.21 (m, 3H), 6.51 (d, J = 8.9 Hz, 
1H), 4.72 (d, J = 3.8 Hz, 1H), 4.34 (td, J = 9.9, 8.9, 3.8 Hz, 1H), 4.14 (dd, J = 10.0, 4.7 Hz, 2H), 4.06 
(t, J = 10.0, 9.1 Hz, 1H), 3.80 (q, 3H), 3.41 (s, 3H).  13C NMR (101 MHz, Chloroform-d) δ 168.7 , 
143.6 , 138.7 , 133.8 , 132.2 , 130.1 , 129.3 , 128.8 , 128.6, 128.1, 127.8 , 127.4 , 125.7 , 102.6 , 
99.1 , 76.9 , 76.2 , 71.5 , 64.2 , 63.5 , 55.5 , 54.5 . 
 
Naphthoyl amide 49:  Yield: 77%;  1H NMR (400 MHz, Chloroform-d) δ 8.65 – 8.58 (m, 1H), 8.40 
– 8.29 (m, 1H), 7.95 (d, J = 8.2 Hz, 2H), 7.91 – 7.81 (m, 0H), 7.73 – 7.61 (m, 15H), 7.56 – 7.51 (m, 
2H), 7.46 – 7.38 (m, 2H), 7.34 – 7.16 (m, 3H), 6.37 (d, J = 9.0 Hz, 1H), 4.82 (d, J = 3.8 Hz, 1H), 
4.46 (td, J = 10.2, 9.0, 3.8 Hz, 1H), 4.15 (dd, J = 9.9, 4.6 Hz, 2H), 4.09 (t, 1H), 3.94 (dd, J = 10.0, 
4.6 Hz, 3H), 3.89 – 3.77 (m, 2H), 3.39 (s, 3H).   13C NMR (101 MHz, Chloroform-d) δ 170.9 , 143.6 
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, 138.7 , 133.9, 131.1 , 130.2 , 129.4 , 128.68, 128.18, 127.8 , 127.5, 126.7 , 125.7 , 125.4, 124.97 
, 102.6 , 99.1 , 76.9 , 76.3 , 71.6 , 64.1 , 63.5 , 55.5 , 54.6.   
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Chapter III. A 2,5-Dimethoxy-4,6-O-Protected Benzylidene Acetal System 
 
Abstract 
 
Low molecular weight gelators (LMWGs) are an important new class of compounds which are of 
special interest because of their wide scope of applications as advanced materials. The Wang 
group has been working on the discovery and the potential applications of sugar based LMWGs. 
We have found that 4,6-benzylidene acetals of  glucopyranoside derivatives form stable gels in 
organic, aqueous, and organic/aqueous solvents. To understand the structural requirements 
and to design acid sensitive LMWGs, we synthesized and characterized a series of 2,5-
dimethoxy benzylidene acetal derivatives of D-glucose and D-glucosamine.  The acid lability of 
such a system is attributed to the electron releasing nature of the methoxy substituents on the 
phenyl ring of the acetal.   
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Introduction 
Low molecular weight gelators (LMWGs) are important compounds within the fields of 
biomedical chemistry and advanced materials, which form supramolecular architectures.  The 
architectures of LMWGs are comprised of a self-assembled, three-dimensional cross-linked 
network of non-covalently bound gelator molecules.  These compounds (LMWGs) possess 
structural properties which allow them to immobilize solvent molecules within their assembly, 
which in-turn engenders a gelatinous material.  The resulting material is principally held 
together by non-covalent attractive forces between the gelator molecules such as: hydrogen 
bonding, hydrophobic forces, π-π interactions, london forces, dipole-dipole interactions, etc.  
Gelators exhibit a variety of morphological properties which, in-turn, lend them to a wide scope 
of potential applications in: pharmaceuticals, food, drug-delivery Potential, biomimetics, 
enzyme-immobilization matrices, liquid crystalline materials, as templates for preparing other 
novel compounds, mechanical actuators, reaction catalysis, and many more such applications 
which are being explored.  Sugar based systems can be both monomeric as in the case with 
LMWGs, and polymeric such as chitosan or polysaccharide systems.  The transferability of gel 
properties from a parent polymeric to a monomeric LMWG system has been wondered. One 
such sugar based system was developed by Rajendran et al, employed chitosan as a gelation 
agent at various molecular weights: 150 KDa, 400 KDa, and 600 KDa (Figure 3.1).  Gelator 
systems employing chitosan have been reported5, but the research performed by Rajendran 
thoroughly explores the different grades of chitosan, as well as the physiochemical 
characteristics to build a release profile of the embedded drug Acyclovir.  Acyclovir is a therapy 
used to combat the Herpes simplex virus.  Their focus was a treatment which released Acyclovir 
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nanoparticles to the ocular surface of the afflicted, using the chitosan gel matrix as the loading 
platform.  To achieve gelation with the chitosan fragments, tri polyphosphate (TPP) anions were 
loaded into the system.  The group concluded that varying the chitosan fragment sizes affected 
the physiochemical and release characteristics of the Acyclovir nanoparticles, and that tuning 
and scaling the size of these gelator molecules can provide a release profile that is specifically 
wanted. 
 
 
Figure 3.1  Chitosan subunit 
Compounds 1 and 2 were used as headgroups for the synthesis of a series of effective low 
molecular weight gelators.  
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Figure 3.2 Glucose and glucosamine based headgroups 1 and 2 
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In this research, we would like to prepare LMWGs with acid labile functional groups in their 
structures.  Such compounds have applications for triggered release delivery systems. Using 
2,5-dimethoxy-4,6-O-benzylidene-α-methyl glucopyranoside  3 or its glucosamine counterpart 
4, various analogues of esters, amides, and carbamates were synthesized and analyzed for their 
gelation properties: 
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4  
Figure 3.3 2,5 Dimthoxy 4,6-protected glucose and glucosamine headgroups 3 and 4 
 
Results and Discussion 
The synthesis of the 2,5-dimethoxy headgroup began with readily available starting material 
2,5-dimethoxy benzaldehyde, which was transformed to the dimethyl acetal 6 employing 
trimethyl orthoformate along with a catalytic quantity of sulfuric acid in methanol under 
refluxing conditions.  The primary substrate, glucosamine 4, was synthesized starting from N-
acetal-D-glucosamine, which was transformed to the 1-MeO N-acetyl-D-glucosamine derivative 
using Amberlite IR 120 acid resin in methanol under refluxing conditions.  The 1-MeO derivative 
was then reacted with dimethyl acetal 6 in DMF in the presence of catalytic p-toluenesulfonic 
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acid at 600C.  To finalize product formation, deacetylation is performed using potassium 
hydroxide in methanol at reflux temperature to produce glucosamine compound 4.   
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Scheme 3.1 Synthesis of 2,5-dimethoxy glucosamine headgroup 
From this 2,5-dimethoxy headgroup, the following amides were synthesized using the acid 
chlorides corresponding to the appended amide tails.  If the acid chloride was not readily 
available it was synthesized from its corresponding carboxylic acid.  These reactions were 
performed under basic conditions using pyridine and the solvent used was almost always 
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dichloromethane.  The temperatures used were typically room temperature, although at the 
addition of the acid chloride starting at 00 C was desired to control the reactivity of the system.   
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Scheme 3.2  Synthesis of various amide analogues of the 2,5-dimethoxybenzyaldehyde-4,6-glucosamine 
system 
 
This is a concern when the competing reaction, which may take place at the C3 -OH of the 
headgroup, is more feasible due to certain reaction conditions or reactants involved.  The 
amide syntheses are illustrated in Scheme 3.2. 
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As gelators, the amides were very efficient.  The solvent mixtures of either water:ethanol and 
water:DMSO gave the best results.  Compound 9 was even a good hydrogelator with a 
minimum gelation concentration (MGC) of 2.5 mg/mL.  This was likely due to the reaching of 
the necessary equilibrium between hydrophobicity and hydrophilicity necessary for gelation. 
The gelling capacity was as well attributed to the critical bonding components such as hydrogen 
bond donors/acceptors and the π stacking system.    
 
Table 3.1  Gelation results of amide analogues 
 Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
8 Quant P I S S S 
9 17 % G (2.5) I S G (20) G (6.7) 
10 100 % I I S G (6.7) G (6.7) 
11 77 % I I Cr G (3.3) G (3.7) 
12 44 % I I S G (20) P 
  
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
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Table 3.2  Gelation results of amide analogues continued 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
13 26 % I I S G (5.7) Gt (5) 
14 31 % I I S P S 
15 19 % G (8.3) I P G (22) G (17.5) 
16 45 % I I P G (3.3) G (3) 
17 97 % I I S P U (20) 
18 62 % I I P G (4) G (4) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
Some difunctionalized amides were as well isolated and tested for their gelation abilities. These 
were functionally amides at the C2 position, yet were esters at the C3 position. Table 3.3 has 
within it the tabulated results, which indicate that such systems may for unstable and even 
some stable gels, yet not as efficiently as the mono-substituted amides, where the C3 is in the 
free –OH form.  This suggests that the Clog P should lean more towards water solubility relative 
to the C2 functionalized amides of this series. 
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Table 3.3  Gelation Results of Difunctionalized Amides 
 
Yield Water Hexane EtOH Water: 
EtOH 
Water: 
DMSO 
19 7% I I S U (20) P 
20 26% I P S I U (20) 
21 24% I I S P G (20) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, 
precipitates 
 
Depriving the gelator system of the hydrogen bond donor gained from the incorporation of the  
N-H from the amide series is one way in which the Wang group theoretically controls the Log P 
values of our gel molecules when designing analogues.  The following series of esters were 
synthesized with this in mind (Scheme 3.4) from headgroup 3 (Scheme 3.3).  The availability of 
two vicinal hydroxyl groups reduces the selectivity for the C2 position, which is indeed favored 
over the C3, yet not to the extent that the reactivity is exclusive to that region.  This is exploited 
by controlling the reaction conditions using excess acid chloride, and usually the C2, C3, and 
dimer are isolated as products from the reactions.  As with the glucosamine series, compound 
23 is synthesized and appended to the glucose monomer derivative 25 at the 4,6-position. 
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   Scheme 3.3  Synthesis of 4,6-protected 2,5-dimethoxy glucose headgroup 3 
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Scheme 3.4  Synthesis of ester analogues for the 2,5-dimethoxybenzyaldehyde-4,6-glucosamine system 
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Of the esters synthesized, none formed gels.  A wide variety of tails ranging from long/short 
chain aliphatic, terminal acetylene, and aromatic in nature were appended and tested for 
gelation, yet to no avail.  A few of the results are listed below, and further exploration of this 
system was ceased due to the fact that it didn’t yield good preliminary results. 
 
Table 3.4  Gelation results of the ester analogues tested 
 
Yield Water Hexane EtOH Water: 
EtOH 
Water: 
DMSO 
26A 11 % I I P P P 
27A 40 % I P S P P 
28A 42 % I P S P P 
29A 13 % I S S P P 
30A 21 % I I S P P 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
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Table 3.5 Monoester Gelator Results 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
26B 17 % I I P P P 
27B 14 % P I S P S 
28B 18 % I I S P P 
29B 33 % I I S P P 
30B 24 % I I P P P 
31B 41 % I I S P P 
32B 74 % I I S P P 
 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
Having an additional hydrogen bond donor and acceptor for our gelator molecules is achieved 
by synthesizing carbamates analogues using the 2,3-dihydroxy glucose headgroup.   
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Scheme 3.5  Synthesis of carbamates LMWGs 
 
The carbamate series proved rather promising, and several dimer molecules were isolated in 
addition to the C2 isomers.  Of the dimers tested, none formed gels.  The C2 isomers prove to 
be efficient gelators in water:ethanol, water:DMSO, and performed surprisingly well in Marvel 
oil.  Marvel oil is very similar in composition to crude oil.  Relative to the amide series, the 
carbamates series may have performed better in such a solvent due to the shift toward a more 
hydrophilic system, with stronger intermolecular interactions present.   
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Table 3.6  Carbamate Gelator Results 
 
Yield Water Hexane EtOH Water: 
EtOH 
2:1 
Water: 
DMSO 
2:1 
33 17 % I I Cr G (5) G (20) 
34 27 % I I Cr  G (5) G (20) 
35 50 % I Cr I G (3.3) G (2.9) 
36 43 % I I Cr  G (4.4) G (2.2) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
This series, incorporating a 2,5-dimethoxy acetal at the 4,6-position of glucose and 
glucosamine, includes: esters, carbamates, and amides, of which the carbamates and amides 
appear to be the more efficient gelators.  Carbamates and amides house an additional 
hydrogen bonding center, and this in conjunction with the hydrophobic tails contributed to 
establishing the necessary hydrophobic/ hydrophilic equilibrium for supramolecular gel-matrix 
assembly.  An acid stability test was performed on amide 11 to analyze the extent to which the 
2,5-dimethoxy system would be labile in the presence of acid.  A more elaborate study will be 
further explored in my fourth chapter.  Gel systems which are responsive to external stimuli in 
an intended fashion, eliciting a desired response, may prove useful in a variety of applications 
O
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O
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such as timed active ingredient release.  The rudimentary experimental setup entails gel 
formation, preferably at a concentration greater than the MGC to ensure gel robustness.  This 
gel is then subjected to an acid solution of known concentration, and the gel decay is recorded 
at intervals.  The following Figure 3.4 illustrates these rudimentary results: 
                 
               
   
    
Figure 3.4  Acid stability test of amide 11 
At the terminal point of the experiment (5hrs), the gel had all but disappeared.  Granted the 
hydrochloric acid concentration was 1M.  A more subtle approach will be employed in future 
experiments, to further build the acid profile of a variety of hydro- and organogelators.  Future 
studies will test the response of the gels to acid at different pHs, and attempt to quantify the 
acid triggered responses.   
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Conclusions 
Several new gelator compounds were synthesized and characterized. This series, incorporating 
a 2,5-dimethoxy acetal at the 4,6-position of glucose and glucosamine, includes: amides, esters, 
and carbamates, of which the carbamates appear to be the more efficient gelators.  
Carbamates house an additional hydrogen bonding center, and this in conjunction with the 
hydrophobic tails perhaps contributed to establishing the necessary hydrophobicity/ 
hydrophilicity equilibrium for supramolecular gel-matrix assembly.   
 
Experimental 
Synthesis of 2,5-dimethoxy benzaldehyde dimethyl acetal  6:  To a 250ml round bottomed flask, 
1 drop of concentrated sulfuric acid was added to 40ml of MeOH and this solution was brought 
to 700C.  To this warm solution was added ~7g of 2,5-dimethoxy benzaldehyde and 1.05 eq of 
trimethylorthoformate.  An 1H NMR was taken at 2hrs which indicated full conversion to the 
desired product. Discontinued reaction and began work-up at 4.25hrs.  The work-up entailed 
quenching the reaction with saturated aqueous NaHCO3, filtering, and then concentrating this 
solution on a roto-vap to yield 9.1g of pure brown liquid product.  Yied: Quantitative 1H NMR 
(400 MHz, Chloroform-d) δ 7.16 – 7.06 (m, 1H), 6.88 – 6.78 (m, 2H), 5.63 (d, J = 0.5 Hz, 1H), 3.79 
(d, J = 10.0 Hz, 7H), 3.37 (d, J = 0.4 Hz, 7H). 
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Methylation of N-acetyl glucosamine  7:     To a 250 round bottom flask, 3.04g of starting 
material was added and dissolved within 60ml of MeOH and brought to reflux (700C). To this 
solution was added 3.09g of acid resin along w/ molecular sieves.  According to 1H NMR @ 
22hrs, reaction conversion was quantitative. Discontinued reaction at 25hrs and concentrated 
on roto-vap. Filtered IR120 resin and washed thoroughly with MeOH, concentrated on roto-vap 
to afford compound 8.  Yield obtained was 84%.  
 
4,6-(2,5-dimethoxy benzylidene) N-acetyl glucosamine headgroup  8:  To a 250ml round bottom 
flask, 2.75g of α-methyl glucosamine 2was dissolved within 17ml of DMF and stirred @ 600C.  
To this solution was added 10mol% of p-TsOH, and then 2.73g (1.1eq) of 2,5-dimethoxy 
benzaldehyde dimethyl acetal.  1H NMR spectra at 4.25hrs and 21.5hrs looked similar (70% 
conv.), therefore added another 0.2 eq of acetal.  When the reaction reached 45hrs, observed 
90% conversion, put rxn on roto-vap for 1/2hr, quenched w/ sodium bicarb, filtered, and blew 
away DMF under N2 overnight. Performed a work-up which entailed dissolving the reaction 
mixture within 150ml of DCM, and then washing this organic phase with water and saturated 
aqueous sodium bicarbonate and drying the organic phase under sodium sulfate.  After this 
mixture was filtered and concentrated, a recrystallization was attempted in EtOH which 
afforded mostly pure product with only DMF as a contaminant.  1H NMR (400 MHz, Chloroform-
d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.90 – 6.77 (m, 3H), 5.91 (s, 1H), 5.85 (d, J = 8.8 Hz, 1H), 4.72 (d, J = 
3.8 Hz, 1H), 4.31 – 4.17 (m, 2H), 3.95 – 3.73 (m, 11H), 3.64 – 3.50 (m, 1H), 3.41 (s, 4H), 2.96 (d, J 
= 4.6 Hz, 2H), 2.88 (d, J = 0.7 Hz, 1H), 2.06 (s, 3H).  13C NMR (101 MHz, Chloroform-d) δ 171.3 , 
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153.6 , 150.8 , 126.0 , 115.9 , 112.3 , 98.8 , 97.1 , 82.2 , 77.3 , 70.7 , 69.0 , 62.4 , 56.3 , 55.7 , 55.2 
, 53.9 , 23.3 . 
 
2,5-dimethoxy-4,6-O-benzylidene-α-MeO-glucosamine 4:     To a 250ml round bottom flask, 
4.04g of the starting material was added and dissolved within 30ml of EtOH.  To this solution 
was added 3.6g of NaOH (3N concentration).  Another 20ml of EtOH was added later to fully 
dissolve reactants (thus diluting the conc. of NaOH).  Quantitative conversion to the desired 
product was observed at 20hrs (as observed by 1H NMR).  Work-up: dissolve in DCM; wash w/ 
water, brine, and then dry using sodium sulfate, filter and concentrate.  1H NMR (400 MHz, 
Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.91 – 6.76 (m, 2H), 5.89 (s, 1H), 5.29 (d, J = 0.8 Hz, 1H), 
4.67 (d, J = 3.5 Hz, 1H), 4.28 – 4.18 (m, 1H), 3.86 – 3.65 (m, 9H), 3.50 – 3.34 (m, 4H), 2.82 – 2.74 
(m, 1H).  13C NMR (101 MHz, Chloroform-d) δ 115.9 , 112.2, 100.8 , 96.9 , 82.0 , 77.0 , 76.6 , 71.5 
, 69.1 , 62.6 , 56.3, 55.7 , 55.4 . 
 
 
 
Amide Syntheses     The common procedure by which the amides were synthesized entails the 
addition of about 50mg of starting material to a flame dried scintillation vial, and then 
dissolving it within 1ml of DCM.  To this solution is added about three equivalents of pyridine 
and this solution is then stirred.  To this, about 1 equivalent of the acid chloride is added. A 
work-up procedure using water and brine extraction may yield pure product, but if not column 
chromatography using a Hex:EtOAc gradient ranging from 6:1 to 1:1 is used.   
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Hexanoyl amide 9:  Yield: 17%;  1H NMR (300 MHz, Chloroform-d) δ 7.16 (d, J = 2.9 Hz, 1H), 6.91 
– 6.76 (m, 2H), 5.92 (s, 1H), 5.81 (d, J = 8.7 Hz, 1H), 4.72 (d, J = 3.8 Hz, 1H), 4.34 – 4.16 (m, 3H), 
3.97 – 3.72 (m, 11H), 3.59 (t, J = 8.7 Hz, 1H), 3.41 (s, 4H), 3.01 (d, J = 3.4 Hz, 1H), 2.25 (t, J = 7.6 
Hz, 3H), 1.67 (q, J = 7.4 Hz, 3H), 1.38 – 1.20 (m, 4H), 0.95 – 0.84 (m, 2H).  13C NMR (101 MHz, 
Chloroform-d) δ 135.4 , 116.1 , 112.5 , 99.0 , 97.2 , 82.4 , 71.0 , 69.2 , 62.6 , 56.5 , 56.0 , 55.5 , 
54.1 , 36.8 , 36.0 , 31.5 , 25.4 , 22.5 , 14.1 . 
 
 
Heptanoyl amide 10: Yield: 100%;  1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 3.0 Hz, 1H), 
6.89 – 6.77 (m, 2H), 5.91 (s, 1H), 5.82 (d, J = 9.1 Hz, 1H), 4.72 (d, J = 3.8 Hz, 1H), 4.31 – 4.18 (m, 
2H), 3.94 – 3.71 (m, 10H), 3.64 – 3.50 (m, 1H), 3.41 (s, 3H), 2.38 – 2.20 (m, 3H), 1.70 – 1.58 (m, 
2H), 1.39 – 1.23 (m, 9H), 1.17 (s, 1H), 0.88 (h, J = 3.2, 2.4 Hz, 4H).  13C NMR (101 MHz, 
Chloroform-d) δ 174.8 , 153.9 , 151.0 , 126.3 , 116.2 , 115.5 , 112.55, 99.1 , 97.3 , 82.4 , 70.8 , 
69.2 , 62.6 , 56.5 , 56.0 , 55.5 , 54.2 , 36.8 , 33.9 , 31.7 , 29.0 , 25.7 , 24.9 , 22.7 , 14.2 . 
 
 
Octanoyl amide 11:  Yield: 77%  1H NMR (400 MHz, Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.89 – 
6.77 (m, 2H), 5.91 (s, 1H), 5.82 (d, J = 8.9 Hz, 1H), 4.72 (d, J = 3.8 Hz, 1H), 4.31 – 4.17 (m, 2H), 3.94 – 3.71 
(m, 10H), 3.64 – 3.48 (m, 1H), 3.41 (s, 3H), 2.25 (dd, J = 8.2, 6.9 Hz, 2H), 1.69 – 1.60 (m, 5H), 1.34 – 1.21 
(m, 10H), 0.91 – 0.79 (m, 3H).   13C NMR (101 MHz, Chloroform-d) δ 174.8 , 153.9 , 151.0 , 126.3 , 
116.3 , 112.5, 99.0 , 97.3 , 82.4 , 77.5 , 70.9 , 69.2 , 62.6 , 56.5 , 56.2 , 55.5 , 54.1 , 52.6 , 36.8 , 
31.8 , 29.2, 25.8 , 22.8 , 14.1. 
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4-Chlorobutanamide 12:  Yield: 44%;  1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, 2H), 6.90 – 
6.83 (m, 4H), 6.80 (s, 1H), 5.91 (s, 4H), 5.86 (d, J = 9.0 Hz, 2H), 5.30 (d, J = 0.9 Hz, 1H), 4.72 (d, J = 
3.7 Hz, 2H), 4.30 – 4.19 (m, 4H), 3.90 (t, J = 9.6 Hz, 2H), 3.79 (s, 16H), 3.77 (s, 5H), 3.68 – 3.54 
(m, 5H), 3.42 (s, 5H), 2.80 (s, 2H), 2.45 (t, 4H), 2.19 – 2.07 (m, 4H), 1.30 – 1.23 (m, 7H), 0.92 – 
0.81 (m, 5H).  
 
 
4-Pentynyl amide 13:  Yield: 26%  1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 1H), 7.15 (d, J = 
3.0 Hz, 2H), 6.89 – 6.77 (m, 4H), 6.01 (d, J = 8.9 Hz, 2H), 5.91 (s, 2H), 4.72 (d, J = 3.8 Hz, 2H), 4.31 
– 4.19 (m, 4H), 3.97 – 3.72 (m, 19H), 3.66 – 3.53 (m, 2H), 3.41 (s, 6H), 2.97 – 2.85 (m, 3H), 2.60 – 
2.35 (m, 8H), 2.02 (t, J = 2.6 Hz, 2H), 1.25 (t, J = 5.7 Hz, 1H), 0.94 – 0.82 (m, 1H).   13C NMR (101 
MHz, Chloroform-d) δ 172.34 , 153.90 , 151.07 , 135.46 , 126.35 , 116.11 , 112.56 (d, J = 9.5 Hz), 
99.11 , 97.30 , 83.04 , 82.29 , 75.81 , 70.71 , 69.73 , 69.23 , 62.72 , 56.56 , 56.02 , 55.57 , 54.22 , 
35.53 , 15.14 . 13C NMR (101 MHz, Chloroform-d) δ 172.3 , 153.9 , 151.0 , 135.6 , 126.3 , 116.11 
, 112.5, 99.1 , 97.3 , 83.0 , 82.2 , 75.8 , 70.7 , 69.7 , 69.2 , 62.7 , 56.5 , 56.0 , 55.5 , 54.2 , 35.5 , 
15.1 . 
  
 
4-Pentynyl amido ester 19:  Yield: 7%;  1H NMR (400 MHz, Chloroform-d) δ 7.18 – 7.09 (m, 3H), 
6.89 – 6.77 (m, 5H), 5.90 (d, J = 9.5 Hz, 3H), 5.83 (s, 3H), 5.30 (t, 9H), 4.72 (d, J = 3.7 Hz, 3H), 
4.41 – 4.23 (m, 5H), 3.92 – 3.68 (m, 26H), 3.41 (s, 7H), 2.56 – 2.34 (m, 18H), 2.07 – 1.96 (m, 2H), 
1.88 (t, J = 2.6 Hz, 2H), 1.26 (d, J = 2.1 Hz, 4H), 0.07 (s, 1H).  13C NMR (101 MHz, Chloroform-d) δ 
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172.3 , 171.0 , 153.8 , 116.0 , 112.5 , 99.2 , 97.2 , 79.3 , 76.9 , 75.7 , 70.7 , 69.6, 69.1, 63.1 , 56.6 , 
56.0 , 55.6 , 52.6 , 35.3 , 33.6 , 33.4 , 14.7 , 14.4 . 
 
 
5-Hexynyl amide 14:  Yield: 31%;  1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 3.0 Hz, 1H), 
6.89 – 6.77 (m, 2H), 5.89 (s, 2H), 4.71 (d, J = 3.8 Hz, 1H), 4.32 – 4.18 (m, 2H), 3.94 – 3.73 (m, 
10H), 3.63 – 3.52 (m, 1H), 3.41 (s, 3H), 2.40 (t, J = 7.3 Hz, 2H), 2.28 (tt, J = 6.6, 2.8 Hz, 2H), 2.02 – 
1.96 (m, 1H), 1.97 – 1.78 (m, 2H).  13C NMR (101 MHz, Chloroform-d) δ 173.7 , 153.9 , 151.0 , 
126.4 , 123.7 , 116.1 , 112.5 , 110.6 , 99.1 , 97.3 , 95.6 , 82.4 , 76.9 , 70.8 , 69.5 , 69.2 , 62.6 , 
56.4, 56.0 , 55.5 , 54.0 , 35.1 , 24.1 , 17.8 . 
 
5-Hexynyl amido ester 20:  Yield: 26%;  1H NMR (400 MHz, Chloroform-d) δ 7.11 (td, J = 3.0 Hz, 
3H), 6.85 (d, J = 8.9 Hz, 6H), 6.81 (d, J = 9.0 Hz, 3H), 5.85 (t, J = 6.2 Hz, 6H), 5.82 (s, 4H), 5.30 (d, 
3H), 5.28 (s, 4H), 4.71 (d, J = 3.6 Hz, 3H), 4.37 – 4.28 (m, 5H), 4.26 (dd, 2H), 3.95 – 3.84 (m, 25H), 
3.79 (s, 8H), 3.76 (s, 8H), 3.42 (s, 8H), 2.41 (t, 20H), 2.33 – 2.26 (m, 5H), 2.23 (dt, J = 6.9, 3.5 Hz, 
5H), 2.18 – 2.12 (m, 4H), 1.98 (t, J = 2.6 Hz, 2H), 1.94 – 1.84 (m, 11H), 1.85 – 1.62 (m, 7H), 0.06 
(s, 1H). 
 
6-Heptynyl amide 15:  Yield:  19%  1H NMR (400 MHz, Chloroform-d) δ 7.26 (s, 1H), 7.15 (d, J = 
3.0 Hz, 1H), 6.90 – 6.77 (m, 2H), 5.91 (s, 1H), 5.82 (d, J = 8.7 Hz, 1H), 4.72 (d, J = 3.8 Hz, 1H), 4.32 
– 4.18 (m, 2H), 3.78 (s, 10H), 3.59 (t, J = 8.8 Hz, 1H), 3.41 (s, 3H), 2.91 (s, 1H), 2.33 – 2.17 (m, 
4H), 1.95 (t, J = 2.6 Hz, 1H), 1.85 – 1.72 (m, 2H), 1.63 – 1.52 (m, 7H).   13C NMR (101 MHz, 
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Chloroform-d) δ 174.1 , 155.3 , 116.1 , 112.5 , 99.0 , 97.3 , 82.4 , 76.9 , 70.9 , 69.2 , 68.8 , 62.6 , 
56.5 , 55.9 , 55.5 , 54.1 , 36.2 , 27.9 , 24.8 , 18.3 . 
 
6-Heptynyl amido ester 21:  Yield: 24%; 1H NMR (400 MHz, Chloroform-d) δ 7.11 (t, 1H), 6.88 – 
6.84 (m, 1H), 6.84 – 6.79 (m, 1H), 5.84 (s, 1H), 5.79 (d, J = 9.4 Hz, 1H), 5.30 (t, J = 10.0 Hz, 1H), 
4.72 (d, J = 3.7 Hz, 1H), 4.32 (td, J = 10.0, 3.7 Hz, 1H), 4.26 (dd, J = 9.9, 4.5 Hz, 1H), 3.88 (dd, 1H), 
3.80 (s, 3H), 3.76 (d, J = 0.8 Hz, 3H), 3.70 (t, J = 9.4 Hz, 1H), 3.41 (s, 3H), 2.29 (q, 2H), 2.23 – 2.14 
(m, 4H), 2.06 (ddd, J = 7.7, 6.7, 2.8 Hz, 2H), 1.95 (td, J = 2.7, 0.9 Hz, 1H), 1.88 (td, J = 2.7, 0.8 Hz, 
1H), 1.75 – 1.61 (m, 5H), 1.55 – 1.50 (m, 1H), 1.48 – 1.40 (m, 2H).   
  
 
10-Undecanoyl amide 16:  Yield: 45%  13C NMR (101 MHz, Chloroform-d) δ 174.72 , 153.89 , 
151.08 , 126.38 , 116.11 , 112.55 (d, J = 8.1 Hz), 99.08 , 97.30 , 84.96 , 82.45 , 70.89 , 69.23 , 
68.36 , 62.67 , 56.56 , 56.01 , 55.52 , 54.13 , 36.84 , 29.47 – 29.02 (m), 28.85 , 28.60 , 25.76 , 
18.57 . 
 
 
Benzoyl amide 17:  Yield: 97%;  1H NMR (400 MHz, Chloroform-d) δ 7.85 – 7.77 (m, 2H), 7.58 – 
7.41 (m, 3H), 7.17 (d, J = 3.0 Hz, 1H), 6.90 – 6.78 (m, 2H), 6.50 (d, J = 8.8 Hz, 1H), 5.94 (s, 1H), 
4.84 (d, J = 3.9 Hz, 1H), 4.45 (ddd, J = 10.3, 8.8, 3.9 Hz, 1H), 4.35 – 4.22 (m, 1H), 4.02 (td, J = 9.6, 
3.3 Hz, 1H), 3.80 (s, 8H), 3.73 – 3.60 (m, 1H), 3.45 (s, 3H), 3.04 (d, J = 3.3 Hz, 1H).  13C NMR (101 
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MHz, Chloroform-d) δ 170.6 , 153.9 , 151.0 , 134.1 , 133.8 , 131.1 , 130.2 , 128.5 , 127.5 , 126.7 , 
126.3 , 125.5, 124.9 , 116.1 , 112.5 , 99.2 , 97.3 , 82.5 , 70.9 , 69.2 , 62.2 , 56.6 , 56.0 , 55.6 , 54.6  
 
 
Naphthoyl amide 18:  Yield: 62%  1H NMR (400 MHz, Chloroform-d) δ 8.39 – 8.30 (m, 1H), 7.97 – 
7.81 (m, 2H), 7.66 (dd, J = 7.0, 1.3 Hz, 1H), 7.60 – 7.42 (m, 3H), 7.17 (d, J = 3.0 Hz, 1H), 6.91 – 
6.78 (m, 2H), 6.37 (d, J = 8.9 Hz, 1H), 5.94 (s, 1H), 4.93 (d, J = 3.9 Hz, 1H), 4.60 – 4.49 (m, 1H), 
4.36 – 4.21 (m, 1H), 4.02 (t, J = 9.7 Hz, 1H), 3.91 – 3.74 (m, 8H), 3.67 (t, J = 9.0 Hz, 1H), 3.42 (s, 
3H).   13C NMR (101 MHz, Chloroform-d) δ 170.6 , 153.9 , 151.0 , 135.4 , 134.1 , 133.8 , 131.1 , 
130.2 , 128.5 , 127.5 , 126.7 , 126.3 , 125.5, 124.9 , 116.1 , 112.5, 99.2 , 97.3 , 82.5 , 70.9 , 69.2 , 
62.8 , 56.6 , 56.0 , 55.6 , 54.6 , 1.2 . 
 
 
 
Synthesis of 4,6-(2,5-dimethoxy benzylidene) glucose headgroup  3  To a 100ml round bottom 
flask, 3.01g of the starting material was added and dissolved within 20ml of DMF, and to this 
solution was added 10mol% p-TsOH and then it was stirred at 600C.  To this solution, 1.1eq of 
2,5-dimethoxy bezaldeyde dimethyl acetal was added (diss. w/in 1ml DCM).  After ~4hrs, 1H 
NMR indicated 90-95% conversion to product, and at 5.66 hrs put solution on a roto-vap to 
remove MeOH and further the reaction.  Quenched rxn with sodium bicarbonate, filtered, and 
performed work-up: DCM/water/brine. Dried under sodium sulfate and then filtered and 
concentrated.  Current Yield:  84%  
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Common procedure for ester synthesis:  To a scintillation vial, about 100mg of the starting 
material headgroup is added to a flame dried scintillation vial and then dissolved with 1ml of 
DCM and stirred. To this solution, about five equivalents of pyridine is added and the solution is 
brought to 00C.  To this cold solution, about 1.3 equivalents of the acid chloride is added and 
the solution is stirred at 00C for another hour and then allowed to approach room temperature.  
If the acid chloride is unavailable then the carboxylic acid is used to prepare it using oxalyl 
chloride and DMF (cat.).  Upon reaction completion, column chromatography is performed 
using a Hex:EtOAc gradient ranging from 20:1 to 1:1 and then flushed.  This typically yields at 
least the C2 and dimer, and sometimes the C3 functionalized esters. 
 
4-Pentynyl ester 26:  Yield 17%;  1H NMR (400 MHz, Chloroform-d) δ 7.15 (d, J = 2.4 Hz, 1H), 
6.88 – 6.83 (m, 1H), 6.80 (d, J = 1.8 Hz, 0H), 5.91 (s, 1H), 4.95 (d, J = 4.0, 1.7 Hz, 1H), 4.83 (dd, J = 
9.6, 3.8, 1.1 Hz, 1H), 4.27 (dd, J = 9.8, 4.6, 1.8 Hz, 1H), 4.19 (t, J = 9.6 Hz, 1H), 3.91 – 3.80 (m, 
1H), 3.79 (s, 1H), 3.78 (s, 2H), 3.58 (t, J = 9.4, 1.8 Hz, 1H), 3.41 (s, 3H), 2.66 (t, 2H), 2.58 – 2.51 
(m, 2H), 1.99 (td, J = 2.6, 0.9 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 171.6 , 153.9 , 151.0 , 
126.1 , 116.2 , 115.5 , 112.5 , 97.7 , 97.3 , 82.6 , 81.6 , 74.1 , 69.3 , 68.8 , 62.3 , 56.5 , 56.0 , 55.7 , 
33.4 , 14.6 , 1.2 .  Diester:  Yield: 11%;  1H NMR (400 MHz, Chloroform-d) δ 7.26 (d, J = 1.8 Hz, 
1H), 7.13 (d, J = 3.1, 1.2 Hz, 2H), 6.89 – 6.83 (m, 4H), 6.84 – 6.70 (m, 2H), 5.80 (d, J = 1.2 Hz, 2H), 
5.60 (t, J = 9.5, 1.3 Hz, 2H), 4.94 (s, 4H), 4.91 (d, J = 3.8, 1.3 Hz, 1H), 4.27 (dd, 2H), 3.94 (td, J = 
9.6, 4.7 Hz, 2H), 3.78 (s, 18H), 3.76 (s, 4H), 3.66 (t, J = 9.7, 1.3 Hz, 2H), 3.41 (s, 6H), 2.66 – 2.54 
(m, 14H), 2.57 – 2.46 (m, 7H), 2.46 – 2.35 (m, 2H), 2.01 – 1.94 (m, 2H), 1.92 – 1.83 (m, 2H).  13C 
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NMR (101 MHz, Chloroform-d) δ 171.3 , 170.7 , 153.9 , 151.0 , 126.2 , 116.3 , 112.4, 97.7 , 97.3 , 
82.5 , 79.4 , 75.8 , 72.0 , 69.54, 69.1, 62.6 , 56.6 , 55.9, 55.6 , 33.4, 14.5, 1.2 . 
 
 
5-Hexynyl ester 27:  C2 Yield: 14%   1H NMR (400 MHz, Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.87 
(ddd, J = 9.0, 3.0, 0.8 Hz, 1H), 6.83 – 6.76 (m, 0H), 5.91 (s, 1H), 4.95 (d, 1H), 4.82 (dd, J = 9.6, 3.8, 0.8 Hz, 
1H), 4.27 (dd, J = 9.8, 4.4 Hz, 1H), 4.16 (t, J = 9.5 Hz, 1H), 3.84 (dd, J = 9.5, 4.5 Hz, 1H), 3.80 (s, 4H), 3.78 
(s, 4H), 3.57 (t, J = 9.3 Hz, 1H), 3.41 (s, 3H), 2.57 (t, J = 7.4 Hz, 2H), 2.28 (td, 2H), 2.04 – 1.94 (m, 1H), 1.92 
– 1.84 (m, 2H).   Diester Yield:  40%;  1H NMR (400 MHz, Chloroform-d) δ 7.13 (d, J = 3.0 Hz, 1H), 6.85 
(dd, J = 9.0, 3.0 Hz, 2H), 6.80 (d, J = 9.0 Hz, 1H), 5.81 (s, 1H), 5.60 (t, J = 9.8 Hz, 1H), 4.95 (d, J = 3.8 Hz, 
2H), 4.90 (dd, J = 9.9, 3.7 Hz, 1H), 4.28 (dd, J = 10.2, 4.9 Hz, 1H), 3.94 (td, J = 9.9, 4.8 Hz, 1H), 3.79 (s, 7H), 
3.77 (s, 3H), 3.66 (t, J = 9.6 Hz, 1H), 3.42 (s, 3H), 2.49 (td, J = 7.3, 2.2 Hz, 2H), 2.40 (t, J = 7.4 Hz, 2H), 2.26 
(td, J = 7.0, 2.7 Hz, 2H), 2.16 (td, J = 7.0, 2.6 Hz, 2H), 1.97 (t, J = 2.6 Hz, 1H), 1.83 (td, J = 7.2, 2.2 Hz, 1H), 
1.79 – 1.69 (m, 2H), 0.07 (s, 1H).  13C NMR (101 MHz, Chloroform-d) δ 172.6, 172.0 , 153.9 , 151.0 , 126.2 
, 116.3 , 112.5 , 112.2 , 97.8 , 97.3 , 97.0 , 83.2, 79.5 , 77.5 , 73.6 , 71.8 , 71.4 , 70.9 , 70.1 , 69.7, 68.9, 
62.6 , 62.2 , 56.6 , 56.0 , 55.5, 32.9, 23.7, 17.8. 
 
6-Heptynyl ester 28:  Yield: 18%;  1H NMR (400 MHz, Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.91 – 
6.84 (m, 1H), 6.83 (s, 1H), 5.91 (s, 1H), 4.95 (d, J = 3.8 Hz, 1H), 4.82 (dd, J = 9.7, 3.8 Hz, 1H), 4.28 
(dd, J = 9.7, 4.4 Hz, 1H), 4.18 (t, J = 9.5 Hz, 1H), 3.84 (dd, J = 9.6, 4.4 Hz, 1H), 3.80 (s, 4H), 3.78 (s, 
3H), 3.57 (t, J = 9.3 Hz, 1H), 3.41 (s, 3H), 2.45 (t, J = 7.2 Hz, 2H), 2.22 (td, J = 7.0, 2.7 Hz, 2H), 2.08 
– 1.94 (m, 1H), 1.84 – 1.72 (m, 2H), 1.64 – 1.52 (m, 8H), 1.44 – 1.16 (m, 1H), 0.92 – 0.82 (m, 3H).  
13C NMR (101 MHz, Chloroform-d) δ 173.4 , 153.5 , 126.1 , 116.2 , 112.5 , 97.8 , 97.3 , 84.1 , 81.7 
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, 77.5 , 73.6 , 71.9 , 71.2 , 70.8 , 69.2 , 68.9 , 62.3 , 56.5 , 56.0 , 55.5 , 33.7 , 27.8 , 24.1 , 18.3 .  
Diester Yield:  42%;  1H NMR (400 MHz, Chloroform-d) δ 7.13 (d, J = 3.0 Hz, 1H), 6.90 – 6.82 (m, 
2H), 6.82 – 6.74 (m, 1H), 5.82 (s, 1H), 5.57 (t, J = 15.4, 9.8 Hz, 1H), 4.96 (d, 2H), 4.90 (dd, 1H), 
4.28 (dd, J = 10.3, 5.3 Hz, 1H), 3.93 (td, J = 9.8, 4.8 Hz, 1H), 3.79 (s, 9H), 3.77 (s, 3H), 3.42 (s, 3H), 
2.38 (td, J = 7.9, 4.1 Hz, 6H), 2.28 (td, J = 7.2, 3.0 Hz, 2H), 2.20 (td, 2H), 2.05 (td, 2H), 1.95 (td, J = 
2.6, 0.7 Hz, 2H), 1.89 (td, J = 2.7, 0.8 Hz, 1H), 1.80 – 1.60 (m, 8H), 1.60 – 1.51 (m, 2H), 1.49 – 
1.40 (m, 1H).  13C NMR (101 MHz, Chloroform-d) δ 173.0 , 172.3 , 153.9 , 151.0 , 126.2 , 116.3 , 
112.5 , 112.2 , 97.8 , 97.3 , 84.0 , 79.5 , 71.7 , 69.2 , 68.9 , 62.6 , 56.6 , 55.9 , 55.6 , 33.8 , 27.9 , 
27.6 , 24.1 , 18.3 , 18.1 . 
 
 
Hexanoyl ester 29:  Yield: 33%;  1H NMR (400 MHz, Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 1H), 6.86 
(dd, J = 11.9, 8.9 Hz, 2H), 6.81 (s, 0H), 5.91 (s, 1H), 4.95 (d, J = 3.8 Hz, 1H), 4.81 (dd, J = 9.7, 3.8 
Hz, 1H), 4.27 (dd, J = 9.8, 4.5 Hz, 1H), 4.17 (td, J = 9.5, 2.4 Hz, 1H), 3.80 (s, 3H), 3.78 (s, 3H), 3.57 
(t, J = 9.3 Hz, 1H), 3.41 (s, 3H), 2.56 – 2.39 (m, 2H), 2.39 (s, 0H), 1.74 – 1.61 (m, 1H), 1.43 – 1.28 
(m, 4H), 0.90 (t, 3H).  13C NMR (101 MHz, Chloroform-d) δ 173.7 , 153.9 , 151.0 , 126.2 , 116.2 , 
112.5 , 97.8 , 97.3 , 81.7 , 73.6 , 69.9 , 68.5 , 62.3 , 56.5 , 56.0 , 55.6 , 34.3 , 31.3 , 24.8 , 22.5 , 
14.1 .  Diester Yield:  13%;  1H NMR (400 MHz, Chloroform-d) δ 7.14 (d, J = 3.1 Hz, 1H), 6.84 (d, J = 3.1 
Hz, 1H), 6.80 (d, J = 9.0 Hz, 1H), 5.80 (s, 1H), 5.60 (t, J = 9.8 Hz, 1H), 4.94 (d, J = 3.8 Hz, 1H), 4.89 (dd, 0H), 
4.27 (dd, J = 10.2, 4.9 Hz, 1H), 4.00 – 3.85 (m, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 3.65 (t, J = 9.7 Hz, 1H), 3.41 
(s, 3H), 2.32 (q, J = 5.6 Hz, 1H), 2.23 (td, J = 3.2 Hz, 1H), 1.61 (q, J = 7.4 Hz, 1H), 1.34 – 1.25 (m, 3H), 1.24 – 
1.16 (m, 3H), 0.89 (t, J = 6.9 Hz, 3H), 0.77 (t, 2H).   
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4-Chlorobutyryl ester 30:  C2 Yield: 24%;   1H NMR (400 MHz, Chloroform-d) δ 7.16 (d, J = 3.0 Hz, 
1H), 6.86 (dd, J = 12.1, 9.1 Hz, 2H), 6.81 (s, 0H), 5.91 (s, 1H), 4.95 (d, J = 3.8 Hz, 1H), 4.83 (dd, J = 
9.7, 3.8 Hz, 1H), 4.28 (dd, J = 9.8, 4.5 Hz, 1H), 4.18 (t, J = 9.5 Hz, 1H), 3.84 (s, 0H), 3.78 (s, 4H), 
3.61 (t, 3H), 3.41 (s, 3H), 2.62 (t, J = 7.2 Hz, 2H), 2.24 – 2.06 (m, 3H).  13C NMR (101 MHz, 
Chloroform-d) δ 172.6 , 155.3 , 153.5 , 151.0 , 126.1 , 116.2 , 112.5 , 97.7 , 97.3 , 81.7 , 73.8 , 
69.2 , 68.9 , 62.2 , 56.5 , 56.0 , 55.6 , 44.0 , 31.4 , 27.8 .   Diester Yield: 21%;  1H NMR (400 MHz, 
Chloroform-d) δ 7.13 (d, J = 3.0 Hz, 1H), 6.90 – 6.77 (m, 2H), 5.81 (s, 1H), 5.59 (t, J = 9.8 Hz, 1H), 
5.30 (s, 1H), 4.96 (d, J = 3.7 Hz, 1H), 4.90 (d, 1H), 4.28 (dd, J = 10.3, 4.8 Hz, 1H), 3.94 (td, J = 9.9, 
4.8 Hz, 1H), 3.81 (s, 7H), 3.77 (s, 3H), 3.66 (t, J = 9.6 Hz, 3H), 3.57 (t, 1H), 3.45 (s, 5H), 2.55 (td, J 
= 7.1, 2.4 Hz, 2H), 2.45 (t, J = 7.1 Hz, 2H), 2.14 – 2.04 (m, 4H), 2.06 – 1.96 (m, 2H), 4.99 – 4.96 
(m, 0H).   
 
Benzoyl ester 31:  Yield: 41%;  1H NMR (400 MHz, Chloroform-d) δ 8.16 – 8.04 (m, 1H), 7.65 – 
7.51 (m, 1H), 7.50 – 7.42 (m, 1H), 7.18 (d, J = 3.1 Hz, 1H), 6.86 (dd, J = 12.2, 9.1 Hz, 1H), 6.82 (s, 
0H), 5.94 (s, 0H), 5.07 (dd, J = 3.6 Hz, 1H), 5.03 (d, J = 3.8 Hz, 0H), 4.36 (t, J = 9.3 Hz, 0H), 4.30 
(dd, 0H), 3.92 (td, J = 9.9, 4.7 Hz, 1H), 3.82 (s, 1H), 3.79 (s, 2H), 3.65 (t, J = 9.4 Hz, 1H), 3.41 (s, 
1H).  13C NMR (101 MHz, Chloroform-d) δ 166.4 , 153.9 , 151.0 , 133.5 , 130.1 , 129.7 , 128.6 , 126.2 , 
116.2 , 112.5 , 98.0 , 97.3 , 81.8 , 74.2 , 69.2 , 62.3 , 56.5 , 56.0 , 55.7 . 
 
Naphthoyl ester 32:  Yield: 74%;  1H NMR (400 MHz, Chloroform-d) δ 8.92 (d, 1H), 8.27 (d, J = 7.3, 
1.3 Hz, 1H), 8.10 – 7.98 (m, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.75 – 7.60 (m, 1H), 7.58 – 7.39 (m, 2H), 
7.19 (d, J = 2.9 Hz, 1H), 6.99 – 6.85 (m, 1H), 6.82 (d, J = 1.0 Hz, 0H), 5.97 (s, 1H), 5.38 – 5.24 (m, 
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0H), 5.18 – 5.12 (m, 1H), 4.42 (t, 1H), 4.32 (dd, 1H), 3.96 (td, J = 9.8, 4.8 Hz, 1H), 3.81 (s, 6H), 
3.70 (t, 1H), 3.46 (s, 2H).   
 
 
General method for carbamate synthesis     The standard procedure by which carbamates are 
synthesized is dependent on the availability of the isocyanate. If the isocyanate needed is 
unavailable, then it must be prepared from the corresponding carboxylic acid via Curtius 
rearrangement.  This is done by first dissolving the acid in 1-1.5 ml of THF (50mg scale), and 
then adding 1-2 equivalents of base, preferably dry triethylamine.  To this solution, 2eq of DPPA 
is added and stirred at about 600C for 2 hours under anhydrous conditions.  Proceeding from 
here, the headgroup is simply added to the solvent mixture at 00C and stirred overnight. 
 
Phenyl carbamate 33:  Yield: 50%;  1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.34 (m, 1H), 7.31 
– 7.27 (m, 1H), 7.26 – 7.18 (m, 1H), 7.19 – 7.08 (m, 1H), 6.87 (dd, J = 9.0, 3.0 Hz, 0H), 6.85 (d, J = 
3.2 Hz, 0H), 5.93 (s, 0H), 5.91 (d, J = 4.6 Hz, 0H), 5.03 (d, J = 5.0 Hz, 1H), 4.84 (dd, 1H), 4.29 (dt, J 
= 10.3, 5.2 Hz, 1H), 4.19 (t, J = 9.6 Hz, 0H), 3.87 (dd, J = 9.5, 4.5 Hz, 0H), 3.79 (s, 2H), 3.77 (s, 1H), 
3.60 (t, J = 9.4 Hz, 0H), 3.45 (s, 1H), 3.43 (d, J = 4.7 Hz, 0H), 2.56 (s, 1H).  13C NMR (101 MHz, 
Chloroform-d) δ 153.9 , 152.9 , 151.0 , 137.7 , 129.2 , 126.1 , 123.8 , 118.9 , 116.1 , 112.6 , 98.2 , 
97.3 , 81.7 , 74.3 , 69.2 , 69.0 , 62.4 , 56.5 , 56.0 , 55.6 . 
 
Benzoyl Carbamate 34:  Yield: 43%;  1H NMR (400 MHz, Chloroform-d) δ 7.39 – 7.30 (m, 1H), 
7.30 – 7.23 (m, 1H), 7.16 (d, J = 3.0 Hz, 0H), 6.86 (dd, J = 9.0, 3.1 Hz, 0H), 6.83 (s, 0H), 5.91 (s, 
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0H), 5.26 (t, J = 5.9 Hz, 0H), 5.00 (d, J = 3.8 Hz, 0H), 4.77 (dd, J = 9.7, 3.8 Hz, 0H), 4.37 (d, J = 5.9 
Hz, 1H), 4.27 (dd, J = 9.5, 4.1 Hz, 0H), 4.14 – 4.11 (m, 0H), 3.83 (s, 1H), 3.79 (s, 2H), 3.59 (t, J = 
9.2 Hz, 0H), 3.43 (s, 1H), 2.62 (s, 0H). 
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Chapter IV. Studies of Stimuli Responsiveness and Trigger Release Applications 
for Advanced Gelator Systems 
 
 
Abstract 
 
Stimuli responsive or trigger release gel systems formed by low molecular weight gelators 
(LMWGs), from the standpoint of having applicable utility, are a testament to the great 
potential that hydrogels and organogels have in forming smart materials.  Inherent to such 
systems are molecular moieties which are sensitive to an external stimulus such as a change in 
pH, irradiation with electromagnetic energy, temperature modifications, and chemical stimuli.  
Selectively incorporating such functionalities or molecules embedded within the gel matrix 
offers predisposed controllable abilities for gel molecules, but as well introduces new problems 
such as the loss of gel properties due to the novel integrations, which may inhibit gelation.  Of 
the many applications for tentative use of supramolecular hydrogel systems, the “Holy Grail” of 
all such uses is said to be drug delivery.  Exploring these new systems not only gives opportunity 
for new material discovery, but as well illustrates LMWG tolerances for functional group 
additions which may prove insightful to the continued effort to produce gelators by design. 
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Introduction 
A comprehensive exploration of the potential applications of physical gels, which are soft novel 
materials formed by molecular aggregates of low molecular weight gelators (LMWGs), is bound 
to reveal valuable uses for such soft macromolecular assemblies.  These assemblies are 
endowed with the property of thermoreversability due to the aggregates being bound in a non-
covalent fashion, which is to say they are bound by weak forces such as hydrogen bonds, Van 
der Waals interactions, π interactions, and ionic forces.  The introduction of an external 
stimulus which either triggers sol-gel transitions, gel swelling, color changes, or gel degradation 
which could lead to the release of embedded molecules, is an approach which makes gelators a 
controllable system with versatile functionality.  For instance, the release of the ‘model’ drugs 
8-aminoquinoline (AQ) and 2-hydroxyquinoline (HQ) were studied and profiled by Jan van Esch 
et al as they were released from gels formed by the gelator molecule N,N’-dibenzoyl-L-cystine 
(DBC).   
N
NH2
8-Aminoquinoline
N OH N O
OH
2-hydroxyquinoline  
Figure 4.1. Model drugs 8-aminoquinoline (AQ) and 2-hydroxyquinoline (HQ) which are entrapped 
within the DBC gel matrix 
 
The supramolecular assembly, being comprised of DBC molecules, allows for it to be responsive 
to pH stimulus, due to the carboxylic acid groups present within the molecule.  Using 8-
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aminoquinoline (AQ) and 2-hydroxyquinoline (HQ) is relevant because the derivatives of 
quinolines are known antimalarial and antileishmanial drugs.  The group selected 8-
aminoquinoine as a model drug because it could interact strongly with the DBC supramolecular 
assembly via not only Van der Waals and hydrogen bonding interactions, but as well through 
the amine interactions with the carboxylic acid groups, i.e. [DBC-COO- +H3N-AQ].  This particular  
 
                                                                
HO S S OH
O
NH HN
O
O O
DBC  
Figure 4.2  N,N’-dibenzoyl-L-cystine 
 
selection represents a characteristic slow release of AQ coinciding with gel degradation.  In 
contrast, a faster release was predicted and observed in the time release profile of HQ, which 
doesn’t have the same strong interaction with the dicarboxylic acid groups.  Gels were formed 
using varying DBC: AQ/HQ concentrations and their release profiles were analyzed using UV/vis 
spectroscopy.  To instigate gel degradation, an NaOH solution was carefully introduced after gel 
formation.  Jan van Esch et al collected the supernatant above each gel formed in DBC at 
varying times as it degraded.  Assuming a degradation system which follows first order kinetics, 
the rate of AQ or HQ release was fit to the equation 1.   
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Equation 1.          Q = Q0 ( 1 – e 
–kt)    
In this first order equation, Q represents either AQ or HQ at time t, and Q0 represents the initial 
quantity of either model drug component (Figure 4.3).   
 
 
Figure 4.3  A first order kinetics fitting for the released percentages and concentrations of HQ and AQ.  
Each line fitting represents the release profiles from gels containing 0.2 wt.% DBC with 1.0mM of 
quinoline embedded within each.  Permission liscence number: 2876830157358. 
 
The above figure illustrates a the kinetics of a first order release profile, yet it was indicated 
that AQ interacts so strongly with the DBC gelator molecules that it follow a gel degredation 
release profile, and does not necessarily follow a first order release.  The release of HQ was 
shown to be about 7 times faster than that of AQ and the differences of these two systems 
illustrates how similar systems may be developed for drug delivery.   
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Molecules which form supramolecular assemblies are found serendipitously on all occasions 
except when designed through analogy.  A recurring theme of an amphiphilic hodgepodge of 
integrated functionalities, which is a sliding scale of properties ranging from hydrophillic to 
hydrophobic in nature, seems to be key to having such gelating abilities.  Salvador Tomas et al 
studied a gel system which housed a hydrophobic, aromatic moiety linked via a disulfide bond, 
and a maleimide linker which could be further functionalized by appending the hydrophillic N-
acetyl-L-cysteine (NAC) amino acid to it (Figure 4.4).   
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S N
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                                                                                     5 
Figure 4.4  N-acetyl-L-cysteine (NAC)molecule featuring multi-stimuli responsive functionalities 
 
This system is part of a rare type of gelators which are known as ‘multiresponsive low molecular 
weight gelators.’  Temperature stimulus which activates the sol-gel transitions and vice versa in 
most gelator systems is exploited with this series of gels, but there are additional stimuli 
responsive characteristics as well.  Due to the presence of the N-acetyl-L-cysteine amino acid 
group, responsiveness to pH is as well inherent to this gel system.  Yet another stimuli-
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responsive feature incorporated within the gelator molecule is the disulfide bond which may be 
reduced.  Although not in all circumstances may the resulting thiols be oxidized back to the 
disulfide linkage, some instances are reported as having reversibility in this regard. Amidst this 
slew of stimuli responsive groups, yet another gel-sol transition may be achieved by hydrolysis 
of the maleimide functionality. As one might expect, the requirements for incorporating 
multiple stimuli responsive functionalities may in itself disrupt a systems ability to gelate.  
None-the-less, compound 5 can gelate water at minimum gelation concentrations ranging from 
0.1 (supergelator range) to 0.86 wt% at various pH readings.  Tomas et al demonstrated this 
gelator as a potential system for drug delivery using vitamin B12, which was released under the 
various gel-sol transition inducing mechanisms.  The following Figure 4.5 illustrates how the 
release rates can be variably controlled by selection of the external stimulus. 
 
 
Figure 4.5  A release profile of vitamin B12 under various gel-sol stimulus conditions.  The square 
represents a reducing solution. The diamond represents the release under acidic pH (5.4 pH).  The circle 
represents the spontaneous hydrolysis of the gelator.  The empty triangle represents the release 
without external stimulus (pH 6.0/ control).  Permission license number:  2877921284114 
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Tomas et al were able to maintain the critical balance of hydrophobicity versus hydrophilicity 
whilst as well introducing several stimuli responsive functionalities in this gel system.  
Furthermore, the use of such a system for drug delivery furthers the continued efforts of 
groups performing analysis of gelator systems for biomedical applications.   
 
Results and Discussion 
Trigger release studies were developed by affecting the gel-sol transitions for two types of 
triggered release gelators: 1) acid sensitive gelators, and 2) base sensitive gelators.  Specifically, 
the acid sensitivity imparted to gelators of the 4,6-protected glucose and glucosamine series 
was done so by adding the electron releasing –OMe groups at the 2,5 position of the phenyl 
rings of glucose compounds  6 and 7.  Having such groups present on the phenyl ring made the 
acetal functionality more acid labile, and therefore acid as an external stimulus could effectively 
provide a gel-sol transition upon introduction to the gel system.  The gelation capabilities of this 
series were well established, and therefore selection of the optimal gelator was simple.   
 
OO
HO
OH
O
OMe
OMe
OMe
OO
HO
NH2
O
OMe
OMe
OMe
 
 
                                                                     6                                                    7 
Scheme 4.6  Glucose and glucosamine gelator headgroups with the acid labile acetals at the 4,6-position 
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The preliminary acid-sensitivity studies entailed performing the gel preparation procedure using 
octanoyl amide compound 8.  After gelation has taken hold, an acid medium of 1 M HCl was 
 
 
      
      
                              8 
 
 
 
 
 
 
Scheme 4.1  Gel-sol transition afforded by acid medium addition 
introduced to cause cleavage of the acid labile acetal group, and in turn caused gel degredation 
as illustrated by Scheme 5.  The degredation process was monitored via photography (Figure 
4.7).  The setup entailed making identical gel vials containing 10 mg of 8, gelating 0.5 mL of a 
2:1 water:DMSO solution.   
Gel Prep Procedure 
Acid  
Medium 
O
HO
NH
OMe
O
O
OMe
OMe O
Acid Hydrolysis
O
HO
NH
OMe
HO
HO
O
OMe
OMe
O
H
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Figure 4.7.  Gel degredation via acid hydrolysis.  From left to right, top to bottom: T0; 40 mins; 1 hr 20 
mins; 3 Hrs 
 
After developing the rudimentary procedure for initiating gel degradation through external 
stimulus, a study to illustrate the capacity of gelator systems to act as trigger release models for 
drug delivery was set up.  Naproxen, a non-steroidal anti-inflammatory drug, or NSAID was 
incorporated into a gel formed by 8, which was subsequently degraded in the presence of acid 
to release the naproxen (NPX).  An illustration of the release profile can be seen in Figure 4.9, in 
which the release occurs over a period of time, and that rate is directly proportional to the gels 
ONa
O
O
Naproxen Sodium (NPX)
                   9  
Figure 4.8  Naproxen sodium, an NSAID 
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degradation in the presence of an acid medium.            
                                              
                                                                                       
Figure 4.9  Predicted time-release mechanism for the release of NPX from a gel formed by 8.  30 mg of 
NPX was dissolved within 0.5 mL of a 2:1 water:DMSO solution and 0.5 mL of a 1 M HCl solution was 
added to several identical gel vials. 
 
Upon addition of the acid medium to the gels formed, contrary to expectations, the gel did not 
degrade over time.  Several photographs at various time intervals were taken to reveal the 
formation of a white barrier, which disallowed gel degradation, as seen in Figure 4.10  This 
barrier 
 
 
 
 
 
Figure 4.10  Gel state after introducing acid medium at: 0.5 hrs; 3 hrs; 4.5 hrs; 25 hrs; 71 hrs; Control 
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formed due to the formation of the acidified form of naproxen, which is insoluble in water.  The 
insolubility of the acid form of naproxen caused a precipitate to form which disallowed gel 
degradation even after 71 hrs.  To investigate the controlled-release profile, the contents of the 
vials were analyzed using spectrophotometric analytical techniques, the first of which is the  
 
 
Graph 1. Absorbance of NPX at different time intervals.   The absorbance for the negative control is 
greater than that for the sample aliquots due to a barrier formation which disallowed NPX release. 
 
absorbance (Graph 1).   The absorbance peaks for NPX of the aliquots taken are relatively 
steady, indicating that the release was in fact disallowed due to the barrier formation.  The 
control negative, which employed only water, has a greater quantity of NPX simply through the 
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diffusion of the NPX through the gel without degredation.  Fluorescence spectroscopy was as 
well performed to reveal similar trends, as seen in Graph 2. 
 
Graph 2.  Fluorescence emission spectra of NPX  
 
The unsuccessful attempt, at least at this juncture, to produce a gel system which acts as a 
model for a drug delivery system prompted me to seek another route in which solubility issues 
would be of no consequence regarding naproxen.  To develop a system which still uses an acid 
medium, however, requires that the acidified form of naproxen not be present upon gel 
degradation.  To achieve this, naproxyl chloride 10 was synthesized, and then subsequently 
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appended to the glucosamine derivative 7 to produce compound 11, as seen in Scheme 4.2.  
Taking this route could effectively lead to naproxyl prodrugs which, when exposed to certain 
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Scheme 4.2  Synthsis of naproxyl amide 11  
 
external stimuli, degrades or is metabolized to the therapeutic agent NPX, indirectly.  Upon 
isolation of compound 11, gel tests were performed to determine this systems’ capacity to 
gelate various organic and aqueous solvents.  As tabulated in Table 4.1, compound 11 forms a 
stable gel in 2:1 water:DMSO at an MGC of 5 mg/mL.  With the introduction of an acid stimulus, 
the gel degrades to produce a glucosamine fragment with the naproxyl amide still in-tact, which 
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theoretically could be further degraded and released via enzymatic interactions.  Several 
photographs were taken to monitor the gel degradation over time under exposure to the acid  
 
Table 4.1 Gelation results for compound 11 
Compound Yield Water Hexane EtOH Water: 
EtOH 
Water: 
DMSO 
11 98% I I S I G (5) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
medium. The gel almost completely degraded over the span of 24 hours.   
 
 
 
 
 
 
 
Figure 4.9  Photographic chronology of acid mediated gel degradation of compound 11. 
+ 
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After development of a few acid based stimuli-responsive profiles of glucose and glucosamine 
based low molecular weight gelators, a base mediated system was desired.  In consideration of 
the fact that these gelator systems house a 4,6-protecting group which is aromatic in nature, 
the naproxyl group was appended to the primary position of N-acetyl 1-MeO glucosamine to 
form compound 12 as seen in Scheme 1.3.  With the trajectory of the aromatic NPX group being 
similar 
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Scheme 1.3.  Synthesis of compound 12 via esterification at the C6 of 1-MeO N-acetyl glucosamine 
 
 to that of any 4,6-appended aromatic groups, it was conjectured that the gelation capabilities 
of such a system would be preserved.  The gelation properties were tested in various solvents 
to reveal that compound 12 does not form a gel in any of the solvents tested (Table 4.2).  At 
this juncture, it was determined that with the C4 –OH increasing the molecules overall cLogP 
was shifted towards a hydrophilic nature, and therefore some hydrophobicity must be restored 
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to the molecule to impart gel properties once again.  This was achieved by introducing an 
octanoyl 
Table 4.2.  Gelation properties of compound 12 
Compound Yield Water Hexane EtOH Water: 
EtOH 
Water: 
DMSO 
12 31% I I S C P 
 U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
group at the amide position, rather than the shorter acetyl group, which likely didn’t contribute 
much to the necessary Van Der Waals interactions necessary for supramolecular assembly to 
form gels.  Compound 14 was synthesized by deprotecting the 2,5-dimethoxy 4,6-benzylidene 
acetal protecting group of the N-octanoyl amide 15, and then subsequently appending naproxyl 
chloride at the primary position to afford the potential pro-drug gelator molecule 14 (Scheme 
4.4).  As predicted, this compound which now has incorporated within it a long aliphatic chain  
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Scheme 4.4  Synthesis of octanoyl amide 14 
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which shifts the aliphatic balance toward a more hydrophobic cLogP, now has the capacity to 
gelate organic/aqueous solvents as shown in Table 4.3.  Compound 14 not only gelates 
water:EtOH and water:DMSO solvent mixtures (2:1), but it as well does so efficiently with MGCs 
lower than 3 mg/mL.  Effectively, this gel system is representative of a gel scaffold 
 
Table 4.3  Gelation results of octanoyl amide 14 
Compound Yield Water Hexane EtOH Water: 
EtOH 
Water: 
DMSO 
        14 49% P I S G (2.1) G (2.8) 
U, unstable gel; G, gel at room temperature; I, insoluble; Cr, crystallizes; S, soluble; P, precipitates 
 
 composed of not only a gelator, but a molecule which is responsive to an external stimulus, 
which upon degradation, releases naproxen from its prodrug parent in a basic medium.  In this 
instance, the naproxen is soluble in aqueous medium because it is in its basic, salt form.  The 
progression of the decay was again monitored by photography, which illustrates the gels decay 
over a period of 1 hour.  The gels formed were at an MGC of 4 mg/mL, and the basic medium 
was a 1 M NaOH solution.   The timed-release profile of the gel formed by compound 14 was 
much more rapid than that of the release profile observed in the case of acetal cleavage in acid 
mediums.  As seen in Figure 4.10, shortly after addition of the basic medium, the gel began to 
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rise and degrade as predicted.  Fluorescence and UV/vis data was obtained to monitor the 
decay  
 
 
 
 
 
  
 
Figure 4.10  Gel degradation of compound 14 via basic medium 
 
and subsequent release of NPX through basic cleavage at the C6 position of molecule 14.  As 
depicted in graphs 3 and 4, the release profile of NPX increases proportionally with time, and 
the control shows a minor quantity of NPX present. 
t
0
 
40 min 
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Graph 3.  UV/vis absorption of NPX cleaved from gel molecule 14 
 
  
Graph 4.  Fluorescence emission spectrum of NPX cleaved from compound 14   
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Conclusions 
 
Two gelator series containing several types of analogues were synthesized and analyzed for 
their gelation properties.  In each series, the amide type gelators consistently performed better 
due to the addition of an –H bond donor center, and as well placement next to the C2 of the 
sugar ring.  Studies of applications for advanced gelator systems led to the discovery of various 
–NPX appended gelator molecules, one of which served as a ‘proof of concept’ for a pro-drug 
gelator molecule. 
 
Experimental 
 
Synthesis of naproxyl chloride 10  To a 50 mL round bottomed flask, 0.303 g (1.2 mmol) was 
added and dissolved within 8 mL of dichloromethane and stirred at 00C for a few minutes until 
all was dissolved.  To this cold solution, 1.1 equivalents (0.15 mL) of oxalyl chloride was added 
drop-wise over 5 minutes.  The solution turned a bright yellow initially, and at this juncture 
added DMF drop-wise until all starting materials were consumed and maintained 00C for an 
hour and allowed reaction to spontaneously proceed to room temperature and stir for an 
additional two hours. After this total 3 hour time period, the reaction was complete as 
indicated by TLC.  Purification simply entails blowing down all volatile contents under nitrogen, 
after which quantitative yield is obtained.  1H NMR (400 MHz, Chloroform-d) δ 7.80 – 7.66 (m, 
6H), 7.35 (dd, J = 8.5, 1.9 Hz, 2H), 7.22 – 7.11 (m, 4H), 4.26 (q, J = 7.0 Hz, 2H), 3.93 (d, J = 0.7 Hz, 
5H), 1.68 (dd, J = 7.1, 0.7 Hz, 5H).  13C NMR (101 MHz, Chloroform-d) δ 175.9 , 158.3 , 134.4 , 
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132.7 , 129.6 , 129.1 , 127.9 , 127.5 , 127.2 , 126.3 , 126.1 , 119.6 , 115.5 , 105.8 , 77.5 , 57.6 , 
55.5 , 18.9 . 
 
Synthesis of N-Naproxyl-4,6-O-Benzylidene-Methyl-α-D-Glucosamine 11  To a scintillation vial, 
0.1069g (0.31 mmol) was added and dissolved within 1 mL of DCM.  To this stirred solution, 1.1 
equivalents (0.0857g) of naproxyl chloride was added along with 3 equivalents (0.08 mL) of 
pyridine.  This reaction was allowed to proceed for 8 hours, after which time it was 
discontinued and an DCM/ aqueous work-up using a saturated ammonium chloride solution 
was performed.  After drying with sodium sulfate and filtering, the organic phase was 
evaporated to provide an off-white powder.  Yield: 98%  1H NMR (400 MHz, Chloroform-d) δ 
7.77 – 7.64 (m, 3H), 7.41 (dd, J = 8.5, 1.9 Hz, 1H), 7.18 – 7.07 (m, 2H), 6.06 (d, J = 8.5 Hz, 1H), 
4.51 (d, J = 3.7 Hz, 1H), 4.43 (dd, J = 12.0, 5.6 Hz, 1H), 4.31 (dd, J = 12.0, 2.2 Hz, 1H), 3.90 (s, 5H), 
3.67 – 3.50 (m, 2H), 3.20 (td, J = 10.0, 8.8 Hz, 1H), 3.04 (s, 3H), 2.01 (s, 3H), 1.59 (d, J = 7.1, 3.4 
Hz, 3H).   
 
 
Synthesis of N-acetyl-6-O-Naproxyl-Methyl-α-D-Glucosamine 12 To a scintillation vial, 0.1016g 
(0.432 mmol) was added and dissolved within 3 mL of DMF, stirred, and brought to 00C.  To this 
cooled solution, 5 equivalents (0.2 mL) of pyridine were added, along with 1.1 equivalents 
(0.1289g) of naproxyl chloride and allowed reaction to proceed overnight.  Upon reaction 
completion, the crude mixture was dried under nitrogen and subsequently purified via column 
chromatography using a hexane:EtOAc gradient ranging from 9:1 to 1:1.  Yield: 31% 1H NMR 
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(400 MHz, Chloroform-d) δ 7.77 – 7.64 (m, 3H), 7.41 (dd, J = 8.5, 1.9 Hz, 1H), 7.18 – 7.07 (m, 
2H), 6.06 (d, J = 8.5 Hz, 1H), 4.51 (d, J = 3.7 Hz, 1H), 4.43 (dd, J = 12.0, 5.6 Hz, 1H), 4.31 (dd, J = 
12.0, 2.2 Hz, 1H), 3.90 (s, 5H), 3.67 – 3.50 (m, 2H), 3.20 (td, J = 10.0, 8.8 Hz, 1H), 3.04 (s, 3H), 
2.01 (s, 3H), 1.59 (s, 3H).  13C NMR (101 MHz, Chloroform-d) δ 174.8 , 172.0 , 157.6 , 135.4 , 
133.6 , 129.1 , 128.8 , 127.1 , 126.3 , 126.0 , 119.0 , 105.5 , 97.9 , 77.3 , 73.7 , 71.1 , 69.5 , 63.4 , 
55.2 , 54.6 , 53.5 , 45.4 , 23.2 , 18.3 . 
 
 
Synthesis of N-Octanoyl Methyl-α-D-Glucosamine 13  To a scintillation vial, 50.4 mg of N-
Octanoyl-4,6-(2,5-dimethoxy) benzylidene Methyl-α-D-Glucosamine was added and dissolved 
within a 85% acetic acid solution and stirred at room temperature for 4.5 hours.  Upon reaction 
completion, an aqueous workup was performed using water, brine, and DCM as the organic 
phase.  After drying with sodium sulfate, filtering, and evaporating the crude mixture was 
purified using column chromatography.  The solvent gradient used was DCM:MeOH ranging 
from 5-25% MeOH in DCM.  Yield:  98%  1H NMR (400 MHz, Chloroform-d) δ 6.39 (d, J = 8.8 Hz, 
2H), 4.62 (d, J = 3.6 Hz, 2H), 3.94 – 3.85 (m, 1H), 3.74 (dd, J = 3.4, 1.7 Hz, 3H), 3.58 – 3.38 (m, 
5H), 3.39 – 3.27 (m, 7H), 3.16 (s, 19H), 2.21 – 2.11 (m, 4H), 1.58 – 1.49 (m, 3H), 1.29 – 1.17 (m, 
22H), 0.85 – 0.76 (m, 11H).   
 
Synthesis of N-Octanoyl-6-O-Naproxyl-Methyl-α-D-Glucosamine 14  To a scintillation vial, 0.037g 
of triol 16 was added and dissolved within 1 mL of DMF along with 5 equivalents (0.05 mL) of 
pyridine and stirred at 00C.  To this cold solution, 1.1 equivalents of naproxyl chloride was 
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added and it was stirred for 12 hrs, after which time an aqueous extraction was performed 
ammonium chloride, brine, and DCM as the organic phase. After isolation of the DCM phase, it 
was subsequently dried using sodium sulfate, filtered, and evaporated.  The crude mixture was 
then loaded onto a column and purified using a DCM:MeOH gradient, in which the product 
eluted at 2% DCM in MeOH.  Yield:  49%  1H NMR (400 MHz, Chloroform-d) δ 7.70 (d, 5H), 7.46 
– 7.35 (m, 2H), 7.18 – 7.06 (m, 3H), 5.77 (d, J = 8.3 Hz, 1H), 4.55 – 4.42 (m, 2H), 4.33 – 4.24 (m, 
1H), 3.91 (s, 8H), 3.62 (ddd, J = 11.6, 5.6, 2.8 Hz, 1H), 3.52 (td, J = 10.2, 9.1 Hz, 1H), 3.38 – 3.28 
(m, 1H), 3.16 (t, J = 9.3 Hz, 1H), 3.08 (s, 3H), 2.20 (t, J = 7.6 Hz, 2H), 1.65 – 1.47 (m, 7H), 1.33 – 
1.17 (m, 11H), 0.91 – 0.82 (m, 4H).  13C NMR (101 MHz, Chloroform-d) δ 175.6 , 175.1 , 157.8 , 
135.7 , 135.3 , 133.9 , 129.4 , 129.11 , 127.4 , 126.67, 126.1 , 119.2 , 115.5 , 105.7 , 98.20 , 76.9 , 
74.6 , 71.3 , 69.6 , 63.5 , 55.5 , 54.9 , 53.7 , 45.6 , 36.7 , 31.8 , 29.9 , 29.2 , 25.7 , 22.8 , 18.4 , 14.2 
. 
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